Human Papillomavirus Infection

Infectious Disease MONDO:0005161 Pathograph 16 Show in embeddings browser Viral Infection

Human papillomavirus (HPV) infection is a common epitheliotropic infection caused by small non-enveloped double-stranded DNA papillomaviruses that infect cutaneous and mucosal stratified squamous epithelium. More than 200 HPV genotypes are recognized and are grouped by mucosal tropism and oncogenic potential into low-risk types (e.g. HPV-6 and HPV-11), which cause benign anogenital warts (condylomata acuminata), common cutaneous warts, and recurrent respiratory papillomatosis, and high-risk types (e.g. HPV-16 and HPV-18), whose persistent infection drives cervical, anal, vulvar, vaginal, penile, and oropharyngeal intraepithelial neoplasia and carcinoma. Most infections are transient and cleared by cell-mediated immunity within 1-2 years; a minority persist and progress. This entry covers the non-neoplastic infection and its benign manifestations and their management, and is distinct from the HPV-associated cancer entries (e.g. Cervical Cancer, HPV-Positive Head and Neck Cancer). Prophylactic L1 virus-like-particle vaccines prevent incident infection by the covered genotypes; established lesions are managed with topical immunomodulators, cytodestructive/antiproliferative agents, and ablative procedures.

Ask OpenScientist

Ask a research question about Human Papillomavirus Infection. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Chapter

⚙

Pathophysiology

Basal Keratinocyte Infection and Genome Establishment

HPV virions gain access to basal keratinocytes of stratified squamous epithelium through microabrasions, binding heparan sulfate proteoglycans and entering by receptor-mediated endocytosis. The viral genome is established as a low-copy nuclear episome in the proliferating basal/parabasal compartment, where E1 and E2 support replication and partitioning.

Basal keratinocyte CL:0002187

Receptor-mediated endocytosis of HPV GO:0019065 ↑ INCREASED

Downstream

Productive Life Cycle Coupled to Keratinocyte Differentiation

Show evidence (1 reference)

PMID:35215808 SUPPORT Other

"In the infected epithelial basal layer, HPV genomes are maintained at a very low copy number, with only limited viral gene expression"

Confirms establishment of a low-copy viral genome in the infected basal epithelial compartment.

Productive Life Cycle Coupled to Keratinocyte Differentiation

The HPV productive life cycle is tightly linked to the epithelial differentiation program. As infected keratinocytes migrate suprabasally and differentiate, viral late promoters activate, E1/E2-driven genome amplification occurs, and L1/L2 capsid proteins are expressed in the most superficial layers, where progeny virions assemble and are shed. E4 disrupts the keratin cytoskeleton to facilitate egress. Low-risk-type productive infection produces the benign hyperplastic warty lesion.

Differentiating keratinocyte CL:0000312

Keratinocyte differentiation GO:0030216 ⚠ ABNORMAL Viral genome replication GO:0019079 ↑ INCREASED Viral release from host cell GO:0019076 ↑ INCREASED

Downstream

Immune Evasion and Persistence

Show evidence (1 reference)

PMID:35215808 SUPPORT Other

"HPV gene expression confers an elevated proliferative potential, a delayed commitment to differentiation, and preferential persistence of the infected cell in the epithelial basal layer"

Supports coupling of the viral program to keratinocyte proliferation and a delayed differentiation commitment that sustains the productive lesion.

Immune Evasion and Persistence

HPV restricts its replication to the epithelium, avoids viremia and cytolysis, downregulates Toll-like receptor and type I interferon signaling, and delays antigen presentation, allowing infection to persist below the threshold of efficient immune detection. Cell-mediated immunity ultimately clears most infections, but immunosuppression (e.g. HIV, transplantation) impairs clearance and predisposes to persistence, extensive warts, and progression.

Keratinocyte CL:0000312

Viral evasion of host immune response GO:0042783 ↑ INCREASED Suppression of host innate immune response GO:0052170 ↑ INCREASED

Downstream

High-Risk Persistence and Transformation

Show evidence (2 references)

PMID:35215808 SUPPORT Other

"factors which allow them to hide from the host immune system"

Supports the immune-evasion basis of HPV persistence in the basal epithelium.

PMID:25362229 SUPPORT Human Clinical

"30% of people with anogenital warts (AGW) have spontaneous regression of lesions"

Documents frequent spontaneous, immune-mediated regression, the counterpart of eventual clearance in most infections.

High-Risk Persistence and Transformation

Persistent high-risk HPV infection can deregulate E6/E7 expression (often accompanying genome integration and loss of E2 repression), driving p53 degradation and pRB inactivation, G1/S checkpoint override, genomic instability, and progression through intraepithelial neoplasia toward invasive carcinoma. In this entry the transformation program is summarized as the bridge to the dedicated HPV-associated cancer entries.

Keratinocyte CL:0000312

Viral genome integration into host DNA GO:0044826 ↑ INCREASED Perturbation of host G1/S checkpoint GO:0039645 ↑ INCREASED

Show evidence (1 reference)

PMID:40216282 SUPPORT Other

"The E6 protein causes degradation of p53 leading to impaired cellular stress response. In contrast, the E7 protein impairs the activity of retinoblastoma protein (pRb) resulting in continuous cell cycle propagation."

Provides the E6/E7 mechanism (p53 degradation, pRb inactivation, cell-cycle override) that underlies high-risk transformation.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Anogenital warts (condylomata acuminata) HP:0032301

Show evidence (1 reference)

PMID:19709100 SUPPORT Human Clinical

"External genital warts (EGWs, condylomata acuminata) are a common, highly contagious disease caused by human papillomavirus (HPV), predominantly"

Identifies external genital warts (condylomata acuminata) as a common HPV disease driven predominantly by HPV-6 and HPV-11.

Cutaneous warts HP:0200043

Show evidence (1 reference)

PMID:22972052 SUPPORT Human Clinical

"Viral warts are a common skin condition, which can range in severity from a minor nuisance that resolve spontaneously to a troublesome, chronic condition."

Establishes cutaneous viral warts as a common, often self-limited skin manifestation of HPV.

Cervical intraepithelial neoplasia HP:0032242

Show evidence (1 reference)

PMID:40216282 SUPPORT Other

"The main aetiological factor for developing cervical cancer is the persistent infection of Human papillomavirus (HPV)."

Persistent high-risk HPV is the causal antecedent of cervical intraepithelial neoplasia and its progression to cervical cancer.

Recurrent respiratory papillomatosis HP:0033001

Show evidence (1 reference)

PMID:40143250 SUPPORT Human Clinical

"Recurrent respiratory papillomatosis (RRP) is a rare, non-malignant disease caused by human papillomavirus (HPV) types 6 and 11."

Confirms RRP as a benign HPV-6/11 papillomatous disease of the respiratory tract.

💊

Medical Actions

Prophylactic HPV Vaccination

Action: vaccination MAXO:0001017

Prophylactic L1 virus-like-particle vaccines (bivalent, quadrivalent, and 9-valent) induce neutralizing antibodies that prevent incident infection by covered genotypes. The 9-valent vaccine covers HPV-6/11 (anogenital warts) and seven high-risk oncogenic types. These vaccines act ONLY at the virion-entry step — they neutralize incoming particles before the genome is established — and therefore do NOT recognize or clear keratinocytes in which infection is already established (the L1 capsid target is not displayed on infected cells). They are preventive, not therapeutic, and do not clear established infection.

Mechanism Target:

INHIBITS Basal Keratinocyte Infection and Genome Establishment — L1 VLP-elicited neutralizing antibodies block virion binding and entry, preventing establishment of the viral genome in basal keratinocytes. The action is confined to this pre-establishment step; because the L1 capsid antigen is not expressed by already-infected cells, prophylactic vaccination has no effect on the productive life cycle, immune-evasion/persistence, or transformation nodes downstream — the model basis for its lack of activity against infected cells.

Show evidence (1 reference)

PMID:37704498 SUPPORT Other

"prophylactic HPV vaccination is not expected to clear active persistent HPV infection or unresected HPV-associated dysplastic tissue remaining after surgery"

Confirms the vaccine acts prophylactically at the entry step and does not clear cells already carrying established HPV infection.

Target Phenotypes: Anogenital warts HP:0032301

Show evidence (2 references)

PMID:40070078 SUPPORT Human Clinical

"showing efficacy of 91.8% to prevent HPV 6-, 11-, 16-, or 18-related external genital lesions"

Randomized-trial evidence that quadrivalent HPV vaccination durably prevents HPV-6/11/16/18-related external genital lesions.

PMID:37704498 SUPPORT Other

"prophylactic HPV vaccination is not expected to clear active persistent HPV infection or unresected HPV-associated dysplastic tissue remaining after surgery"

Supports the framing that the vaccine is prophylactic and not therapeutic for established infection.

Therapeutic HPV Vaccination (E6/E7-directed)

Action: vaccination MAXO:0001017

Investigational therapeutic vaccines that, unlike prophylactic L1 VLP vaccines, are designed to act ON established infection. They present the HPV E6 and E7 oncoproteins — which ARE expressed by infected/transformed keratinocytes — via DNA, synthetic long-peptide, viral-vector, or mRNA platforms to prime E6/E7-specific cytotoxic T lymphocytes that recognize and kill already-infected cells. The furthest-advanced example, the HPV-16/18 E6/E7 DNA vaccine VGX-3100, produced histologic regression of CIN2/3 in a randomized phase 2b trial; synthetic long-peptide (ISA101), viral-vector, and mRNA candidates are in trials, often combined with immune-checkpoint blockade in HPV-driven cancers. Still investigational and not yet standard of care.

Mechanism Target:

INHIBITS High-Risk Persistence and Transformation — E6/E7-specific cytotoxic T cells recognize and kill keratinocytes that express the E6/E7 oncoproteins, eliminating persistently infected/transformed cells and driving histologic regression — the mechanistic contrast with prophylactic vaccination, which cannot reach infected cells.

Show evidence (1 reference)

PMID:26386540 SUPPORT Human Clinical

"VGX-3100, synthetic plasmids targeting HPV-16 and HPV-18 E6 and E7 proteins, delivered by electroporation, would cause histopathological regression in women with CIN2/3"

Demonstrates that an E6/E7-directed therapeutic vaccine acts on established (infected/dysplastic) cervical epithelium to cause regression.

INHIBITS Immune Evasion and Persistence — By supplying strong E6/E7 antigen presentation and T-cell help, therapeutic vaccination counteracts the weak immune visibility that normally allows HPV to persist.

Target Phenotypes: Cervical intraepithelial neoplasia HP:0032242

Show evidence (1 reference)

PMID:26386540 SUPPORT Human Clinical

"VGX-3100 is the first therapeutic vaccine to show efficacy against CIN2/3 associated with HPV-16 and HPV-18."

Randomized phase 2b evidence that an E6/E7-targeted therapeutic vaccine achieves histologic regression of established high-grade cervical dysplasia.

Imiquimod

Action: Pharmacotherapy NCIT:C15986

Agent: imiquimod CHEBI:36704

Topical Toll-like receptor 7 agonist that stimulates local innate and cell-mediated immune responses (interferon-alpha and other cytokines) to clear external anogenital warts; patient-applied.

Mechanism Target:

INHIBITS Immune Evasion and Persistence — TLR7 agonism triggers local interferon-alpha and pro-inflammatory cytokine release and recruits cell-mediated immunity, counteracting the immune evasion that lets the productive infection persist.

Target Phenotypes: Anogenital warts HP:0032301

Show evidence (1 reference)

PMID:25362229 SUPPORT Human Clinical

"imiquimod was superior to placebo in achieving complete and partial regression"

Cochrane review evidence that patient-applied imiquimod clears anogenital warts better than placebo.

Podophyllotoxin (podofilox)

Action: Pharmacotherapy NCIT:C15986

Agent: podophyllotoxin CHEBI:50305

Patient-applied topical antimitotic that arrests wart keratinocytes in metaphase and causes local tissue necrosis of external anogenital warts.

Mechanism Target:

INHIBITS Productive Life Cycle Coupled to Keratinocyte Differentiation — Antimitotic metaphase arrest and necrosis of the productively infected, proliferating wart keratinocytes. The agent clears the visible lesion but does not eradicate the basal-layer reservoir, so recurrence can follow.

Target Phenotypes: Anogenital warts HP:0032301

Show evidence (1 reference)

PMID:31675442 SUPPORT Human Clinical

"podophyllotoxin 0·5% solution (odds ratio 1·94, 95% confidence interval 1·02-3·71) was significantly more efficacious than imiquimod 5% cream for lesion clearance"

Network meta-analysis found podophyllotoxin 0.5% significantly more efficacious than imiquimod 5% cream for external genital wart lesion clearance.

Sinecatechins

Action: Pharmacotherapy NCIT:C15986

Agent: epigallocatechin gallate CHEBI:4806

Topical green-tea (Camellia sinensis) catechin extract, standardized on epigallocatechin gallate, applied to external anogenital warts; immunostimulatory and antiproliferative.

Mechanism Target:

MODULATES Productive Life Cycle Coupled to Keratinocyte Differentiation — Green-tea catechins exert antiproliferative and immunostimulatory effects on the productively infected wart epithelium, promoting clearance of the lesion.

Target Phenotypes: Anogenital warts HP:0032301

Show evidence (2 references)

PMID:19709100 SUPPORT Human Clinical

"Polyphenon E ointment is effective and well tolerated in the treatment of EGWs."

Phase III trial data that sinecatechins (Polyphenon E) ointment effectively clears external genital warts.

PMID:19709100 SUPPORT Human Clinical

"Green tea catechins have been identified for their immunostimulatory, antiproliferative and antitumour properties."

Supports the immunostimulatory/antiproliferative mechanism attributed to the green-tea catechin extract.

Trichloroacetic acid

Action: Pharmacotherapy NCIT:C15986

Agent: trichloroacetic acid CHEBI:30956

Provider-applied caustic agent that chemically coagulates and destroys wart tissue; suitable for external and mucosal anogenital warts including in pregnancy.

Mechanism Target:

INHIBITS Productive Life Cycle Coupled to Keratinocyte Differentiation — Chemical coagulation and destruction of the productively infected wart tissue; lesion-directed cytodestruction that does not clear the basal reservoir.

Target Phenotypes: Anogenital warts HP:0032301

Show evidence (1 reference)

PMID:39194148 PARTIAL Human Clinical

"Combination therapy of TCA and podophyllin leads to complete wart clearance"

Case-report evidence that provider-applied trichloroacetic acid contributes to clearance of anogenital (condylomata acuminata) warts.

Cryotherapy

Action: cryosurgery Ontology label: Cryosurgery NCIT:C15215

Provider-applied cryosurgery with liquid nitrogen produces cytolytic freezing of wart tissue; a first-line ablative option for cutaneous and anogenital warts, usable in pregnancy.

Mechanism Target:

INHIBITS Productive Life Cycle Coupled to Keratinocyte Differentiation — Cytolytic freezing destroys the productively infected lesion; because the basal-layer reservoir may persist, warts can recur after ablation.

Target Phenotypes: Anogenital warts HP:0032301 Cutaneous warts (verrucae) HP:0200043

Show evidence (1 reference)

PMID:33433720 SUPPORT Human Clinical

"Cryotherapy is a first-line treatment."

Randomized-trial report identifying cryotherapy as a first-line ablative treatment for anogenital warts.

Surgical/Ablative Removal

Action: surgical procedure MAXO:0000004

Physical removal of warts by surgical excision, electrosurgery, curettage, or laser ablation; used for large, extensive, or refractory lesions and for recurrent respiratory papillomatosis debulking.

Mechanism Target:

INHIBITS Productive Life Cycle Coupled to Keratinocyte Differentiation — Physical removal or ablation of papillomatous lesions (including repeated laser debulking in recurrent respiratory papillomatosis) reduces disease burden but does not eradicate latent basal-layer infection, so recurrence is common.

Target Phenotypes: Anogenital warts HP:0032301 Laryngeal papillomatosis HP:0033001

Show evidence (1 reference)

PMID:40143250 SUPPORT Human Clinical

"It is more aggressive in younger patients, necessitating frequent surgical interventions."

Documents that recurrent respiratory papillomatosis requires frequent surgical (laser-ablative) interventions to debulk airway papillomas.

{ }

Source YAML

click to show

category: Infectious Disease
name: Human Papillomavirus Infection
creation_date: "2026-07-01T00:00:00Z"
description: >-
  Human papillomavirus (HPV) infection is a common epitheliotropic infection caused by
  small non-enveloped double-stranded DNA papillomaviruses that infect cutaneous and mucosal
  stratified squamous epithelium. More than 200 HPV genotypes are recognized and are grouped
  by mucosal tropism and oncogenic potential into low-risk types (e.g. HPV-6 and HPV-11),
  which cause benign anogenital warts (condylomata acuminata), common cutaneous warts, and
  recurrent respiratory papillomatosis, and high-risk types (e.g. HPV-16 and HPV-18), whose
  persistent infection drives cervical, anal, vulvar, vaginal, penile, and oropharyngeal
  intraepithelial neoplasia and carcinoma. Most infections are transient and cleared by
  cell-mediated immunity within 1-2 years; a minority persist and progress. This entry covers
  the non-neoplastic infection and its benign manifestations and their management, and is
  distinct from the HPV-associated cancer entries (e.g. Cervical Cancer, HPV-Positive Head
  and Neck Cancer). Prophylactic L1 virus-like-particle vaccines prevent incident infection
  by the covered genotypes; established lesions are managed with topical immunomodulators,
  cytodestructive/antiproliferative agents, and ablative procedures.
parents:
- Viral Infection
disease_term:
  preferred_term: human papillomavirus infection
  term:
    id: MONDO:0005161
    label: human papilloma virus infection
classifications:
  harrisons_chapter:
  - classification_value: INFECTIOUS_DISEASES
infectious_agent:
- name: Human papillomavirus (HPV)
  infectious_agent_term:
    preferred_term: Human papillomavirus
    term:
      id: NCBITaxon:10566
      label: Human papillomavirus
  description: >-
    A small (~55 nm), non-enveloped virus with a circular ~8 kb double-stranded DNA genome
    encoding early (E1, E2, E4, E5, E6, E7) and late (L1, L2) proteins. The L1 major capsid
    protein self-assembles into virus-like particles, the basis of prophylactic vaccines.
    High-risk types encode E6 and E7 oncoproteins that inactivate p53 and pRB.
  evidence:
  - reference: PMID:40216282
    reference_title: "Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The E6 protein causes degradation of p53 leading to impaired cellular stress response. In contrast, the E7 protein impairs the activity of retinoblastoma protein (pRb) resulting in continuous cell cycle propagation."
    explanation: >-
      Establishes the E6/E7 oncoprotein functions (p53 degradation and pRb inactivation)
      that define high-risk HPV biology described here.

transmission:
- name: Sexual/skin-to-skin contact
  description: >-
    Genital HPV types are transmitted primarily through sexual and other genital skin-to-skin
    contact; cutaneous types spread by non-sexual skin contact and fomites; vertical
    transmission at delivery can seed juvenile-onset recurrent respiratory papillomatosis.
  evidence:
  - reference: PMID:33101476
    reference_title: "Non-sexual HPV transmission and role of vaccination for a better future (Review)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The route of HPV transmission is primarily through skin-to-skin or skin-to-mucosa contact. Sexual transmission is the most documented, but there have been studies suggesting non-sexual courses."
    explanation: >-
      Documents skin-to-skin/skin-to-mucosa contact as the primary HPV transmission route,
      with sexual transmission the best documented.
  - reference: PMID:33101476
    reference_title: "Non-sexual HPV transmission and role of vaccination for a better future (Review)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Vertical transmission from mother to child is another HPV transfer course."
    explanation: >-
      Supports vertical (mother-to-child) transmission, the route implicated in
      juvenile-onset recurrent respiratory papillomatosis.

pathophysiology:
- name: Basal Keratinocyte Infection and Genome Establishment
  description: >-
    HPV virions gain access to basal keratinocytes of stratified squamous epithelium through
    microabrasions, binding heparan sulfate proteoglycans and entering by receptor-mediated
    endocytosis. The viral genome is established as a low-copy nuclear episome in the
    proliferating basal/parabasal compartment, where E1 and E2 support replication and
    partitioning.
  cell_types:
  - preferred_term: Basal keratinocyte
    term:
      id: CL:0002187
      label: basal cell of epidermis
  biological_processes:
  - preferred_term: Receptor-mediated endocytosis of HPV
    term:
      id: GO:0019065
      label: receptor-mediated endocytosis of virus by host cell
    modifier: INCREASED
  evidence:
  - reference: PMID:35215808
    reference_title: "The Reservoir of Persistent Human Papillomavirus Infection; Strategies for Elimination Using Anti-Viral Therapies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In the infected epithelial basal layer, HPV genomes are maintained at a very low copy number, with only limited viral gene expression"
    explanation: >-
      Confirms establishment of a low-copy viral genome in the infected basal epithelial
      compartment.
  downstream:
  - target: Productive Life Cycle Coupled to Keratinocyte Differentiation

- name: Productive Life Cycle Coupled to Keratinocyte Differentiation
  description: >-
    The HPV productive life cycle is tightly linked to the epithelial differentiation program.
    As infected keratinocytes migrate suprabasally and differentiate, viral late promoters
    activate, E1/E2-driven genome amplification occurs, and L1/L2 capsid proteins are expressed
    in the most superficial layers, where progeny virions assemble and are shed. E4 disrupts
    the keratin cytoskeleton to facilitate egress. Low-risk-type productive infection produces
    the benign hyperplastic warty lesion.
  cell_types:
  - preferred_term: Differentiating keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: Keratinocyte differentiation
    term:
      id: GO:0030216
      label: keratinocyte differentiation
    modifier: ABNORMAL
  - preferred_term: Viral genome replication
    term:
      id: GO:0019079
      label: viral genome replication
    modifier: INCREASED
  - preferred_term: Viral release from host cell
    term:
      id: GO:0019076
      label: viral release from host cell
    modifier: INCREASED
  evidence:
  - reference: PMID:35215808
    reference_title: "The Reservoir of Persistent Human Papillomavirus Infection; Strategies for Elimination Using Anti-Viral Therapies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HPV gene expression confers an elevated proliferative potential, a delayed commitment to differentiation, and preferential persistence of the infected cell in the epithelial basal layer"
    explanation: >-
      Supports coupling of the viral program to keratinocyte proliferation and a delayed
      differentiation commitment that sustains the productive lesion.
  downstream:
  - target: Immune Evasion and Persistence

- name: Immune Evasion and Persistence
  description: >-
    HPV restricts its replication to the epithelium, avoids viremia and cytolysis, downregulates
    Toll-like receptor and type I interferon signaling, and delays antigen presentation, allowing
    infection to persist below the threshold of efficient immune detection. Cell-mediated immunity
    ultimately clears most infections, but immunosuppression (e.g. HIV, transplantation) impairs
    clearance and predisposes to persistence, extensive warts, and progression.
  cell_types:
  - preferred_term: Keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: Viral evasion of host immune response
    term:
      id: GO:0042783
      label: symbiont-mediated evasion of host immune response
    modifier: INCREASED
  - preferred_term: Suppression of host innate immune response
    term:
      id: GO:0052170
      label: symbiont-mediated suppression of host innate immune response
    modifier: INCREASED
  evidence:
  - reference: PMID:35215808
    reference_title: "The Reservoir of Persistent Human Papillomavirus Infection; Strategies for Elimination Using Anti-Viral Therapies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "factors which allow them to hide from the host immune system"
    explanation: >-
      Supports the immune-evasion basis of HPV persistence in the basal epithelium.
  - reference: PMID:25362229
    reference_title: "Imiquimod for anogenital warts in non-immunocompromised adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "30% of people with anogenital warts (AGW) have spontaneous regression of lesions"
    explanation: >-
      Documents frequent spontaneous, immune-mediated regression, the counterpart of
      eventual clearance in most infections.
  downstream:
  - target: High-Risk Persistence and Transformation

- name: High-Risk Persistence and Transformation
  conforms_to: "viral_oncogenesis#Host Tumor Suppressor Inactivation and Signaling Hijack"
  description: >-
    Persistent high-risk HPV infection can deregulate E6/E7 expression (often accompanying
    genome integration and loss of E2 repression), driving p53 degradation and pRB inactivation,
    G1/S checkpoint override, genomic instability, and progression through intraepithelial
    neoplasia toward invasive carcinoma. In this entry the transformation program is summarized
    as the bridge to the dedicated HPV-associated cancer entries.
  cell_types:
  - preferred_term: Keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: Viral genome integration into host DNA
    term:
      id: GO:0044826
      label: viral genome integration into host DNA
    modifier: INCREASED
  - preferred_term: Perturbation of host G1/S checkpoint
    term:
      id: GO:0039645
      label: symbiont-mediated perturbation of host cell cycle G1/S transition checkpoint
    modifier: INCREASED
  evidence:
  - reference: PMID:40216282
    reference_title: "Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The E6 protein causes degradation of p53 leading to impaired cellular stress response. In contrast, the E7 protein impairs the activity of retinoblastoma protein (pRb) resulting in continuous cell cycle propagation."
    explanation: >-
      Provides the E6/E7 mechanism (p53 degradation, pRb inactivation, cell-cycle override)
      that underlies high-risk transformation.

phenotypes:
- name: Anogenital warts (condylomata acuminata)
  description: >-
    Benign verrucous or papular lesions of the external genitalia, perineum, perianal skin,
    and anal canal caused predominantly by low-risk HPV-6 and HPV-11.
  phenotype_term:
    preferred_term: Anogenital warts
    term:
      id: HP:0032301
      label: Genital warts
  evidence:
  - reference: PMID:19709100
    reference_title: "Polyphenon E: a new treatment for external anogenital warts."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "External genital warts (EGWs, condylomata acuminata) are a common, highly contagious disease caused by human papillomavirus (HPV), predominantly"
    explanation: >-
      Identifies external genital warts (condylomata acuminata) as a common HPV disease
      driven predominantly by HPV-6 and HPV-11.

- name: Cutaneous warts
  description: >-
    Common warts (verruca vulgaris), plantar warts, and flat warts of keratinized skin caused
    by cutaneous HPV types.
  phenotype_term:
    preferred_term: Cutaneous warts (verrucae)
    term:
      id: HP:0200043
      label: Verrucae
  evidence:
  - reference: PMID:22972052
    reference_title: "Topical treatments for cutaneous warts."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Viral warts are a common skin condition, which can range in severity from a minor nuisance that resolve spontaneously to a troublesome, chronic condition."
    explanation: >-
      Establishes cutaneous viral warts as a common, often self-limited skin manifestation
      of HPV.

- name: Cervical intraepithelial neoplasia
  description: >-
    Squamous intraepithelial lesions of the cervix (CIN 1-3) reflecting persistent high-risk
    HPV infection, a precancerous continuum detected by cytology/HPV testing.
  phenotype_term:
    preferred_term: Cervical intraepithelial neoplasia
    term:
      id: HP:0032242
      label: Cervical intraepithelial neoplasia
  evidence:
  - reference: PMID:40216282
    reference_title: "Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The main aetiological factor for developing cervical cancer is the persistent infection of Human papillomavirus (HPV)."
    explanation: >-
      Persistent high-risk HPV is the causal antecedent of cervical intraepithelial
      neoplasia and its progression to cervical cancer.

- name: Recurrent respiratory papillomatosis
  description: >-
    Recurrent benign papillomas of the larynx and respiratory tract caused by HPV-6/11,
    with juvenile-onset disease acquired via vertical transmission.
  phenotype_term:
    preferred_term: Laryngeal papillomatosis
    term:
      id: HP:0033001
      label: Laryngeal papilloma
  evidence:
  - reference: PMID:40143250
    reference_title: "Therapeutic Impact of Gardasil in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recurrent respiratory papillomatosis (RRP) is a rare, non-malignant disease caused by human papillomavirus (HPV) types 6 and 11."
    explanation: >-
      Confirms RRP as a benign HPV-6/11 papillomatous disease of the respiratory tract.

treatments:
- name: Prophylactic HPV Vaccination
  description: >-
    Prophylactic L1 virus-like-particle vaccines (bivalent, quadrivalent, and 9-valent)
    induce neutralizing antibodies that prevent incident infection by covered genotypes.
    The 9-valent vaccine covers HPV-6/11 (anogenital warts) and seven high-risk oncogenic
    types. These vaccines act ONLY at the virion-entry step — they neutralize incoming
    particles before the genome is established — and therefore do NOT recognize or clear
    keratinocytes in which infection is already established (the L1 capsid target is not
    displayed on infected cells). They are preventive, not therapeutic, and do not clear
    established infection.
  therapeutic_modality: VACCINE
  treatment_term:
    preferred_term: vaccination
    term:
      id: MAXO:0001017
      label: vaccination
  target_mechanisms:
  - target: Basal Keratinocyte Infection and Genome Establishment
    treatment_effect: INHIBITS
    description: >-
      L1 VLP-elicited neutralizing antibodies block virion binding and entry, preventing
      establishment of the viral genome in basal keratinocytes. The action is confined to
      this pre-establishment step; because the L1 capsid antigen is not expressed by
      already-infected cells, prophylactic vaccination has no effect on the productive life
      cycle, immune-evasion/persistence, or transformation nodes downstream — the model
      basis for its lack of activity against infected cells.
    evidence:
    - reference: PMID:37704498
      reference_title: "Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "prophylactic HPV vaccination is not expected to clear active persistent HPV infection or unresected HPV-associated dysplastic tissue remaining after surgery"
      explanation: >-
        Confirms the vaccine acts prophylactically at the entry step and does not clear
        cells already carrying established HPV infection.
  target_phenotypes:
  - preferred_term: Anogenital warts
    term:
      id: HP:0032301
      label: Genital warts
  evidence:
  - reference: PMID:40070078
    reference_title: "Efficacy of human papillomavirus vaccines in the prevention of male genital diseases: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "showing efficacy of 91.8% to prevent HPV 6-, 11-, 16-, or 18-related external genital lesions"
    explanation: >-
      Randomized-trial evidence that quadrivalent HPV vaccination durably prevents
      HPV-6/11/16/18-related external genital lesions.
  - reference: PMID:37704498
    reference_title: "Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "prophylactic HPV vaccination is not expected to clear active persistent HPV infection or unresected HPV-associated dysplastic tissue remaining after surgery"
    explanation: >-
      Supports the framing that the vaccine is prophylactic and not therapeutic for
      established infection.

- name: Therapeutic HPV Vaccination (E6/E7-directed)
  description: >-
    Investigational therapeutic vaccines that, unlike prophylactic L1 VLP vaccines, are
    designed to act ON established infection. They present the HPV E6 and E7 oncoproteins
    — which ARE expressed by infected/transformed keratinocytes — via DNA, synthetic
    long-peptide, viral-vector, or mRNA platforms to prime E6/E7-specific cytotoxic T
    lymphocytes that recognize and kill already-infected cells. The furthest-advanced
    example, the HPV-16/18 E6/E7 DNA vaccine VGX-3100, produced histologic regression of
    CIN2/3 in a randomized phase 2b trial; synthetic long-peptide (ISA101), viral-vector,
    and mRNA candidates are in trials, often combined with immune-checkpoint blockade in
    HPV-driven cancers. Still investigational and not yet standard of care.
  therapeutic_modality: VACCINE
  treatment_term:
    preferred_term: vaccination
    term:
      id: MAXO:0001017
      label: vaccination
  target_mechanisms:
  - target: High-Risk Persistence and Transformation
    treatment_effect: INHIBITS
    description: >-
      E6/E7-specific cytotoxic T cells recognize and kill keratinocytes that express the
      E6/E7 oncoproteins, eliminating persistently infected/transformed cells and driving
      histologic regression — the mechanistic contrast with prophylactic vaccination, which
      cannot reach infected cells.
    evidence:
    - reference: PMID:26386540
      reference_title: "Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "VGX-3100, synthetic plasmids targeting HPV-16 and HPV-18 E6 and E7 proteins, delivered by electroporation, would cause histopathological regression in women with CIN2/3"
      explanation: >-
        Demonstrates that an E6/E7-directed therapeutic vaccine acts on established
        (infected/dysplastic) cervical epithelium to cause regression.
  - target: Immune Evasion and Persistence
    treatment_effect: INHIBITS
    description: >-
      By supplying strong E6/E7 antigen presentation and T-cell help, therapeutic
      vaccination counteracts the weak immune visibility that normally allows HPV to persist.
  target_phenotypes:
  - preferred_term: Cervical intraepithelial neoplasia
    term:
      id: HP:0032242
      label: Cervical intraepithelial neoplasia
  evidence:
  - reference: PMID:26386540
    reference_title: "Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "VGX-3100 is the first therapeutic vaccine to show efficacy against CIN2/3 associated with HPV-16 and HPV-18."
    explanation: >-
      Randomized phase 2b evidence that an E6/E7-targeted therapeutic vaccine achieves
      histologic regression of established high-grade cervical dysplasia.

- name: Imiquimod
  description: >-
    Topical Toll-like receptor 7 agonist that stimulates local innate and cell-mediated
    immune responses (interferon-alpha and other cytokines) to clear external anogenital
    warts; patient-applied.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: imiquimod
      term:
        id: CHEBI:36704
        label: imiquimod
  target_mechanisms:
  - target: Immune Evasion and Persistence
    treatment_effect: INHIBITS
    description: >-
      TLR7 agonism triggers local interferon-alpha and pro-inflammatory cytokine release
      and recruits cell-mediated immunity, counteracting the immune evasion that lets the
      productive infection persist.
  target_phenotypes:
  - preferred_term: Anogenital warts
    term:
      id: HP:0032301
      label: Genital warts
  evidence:
  - reference: PMID:25362229
    reference_title: "Imiquimod for anogenital warts in non-immunocompromised adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "imiquimod was superior to placebo in achieving complete and partial regression"
    explanation: >-
      Cochrane review evidence that patient-applied imiquimod clears anogenital warts
      better than placebo.

- name: Podophyllotoxin (podofilox)
  description: >-
    Patient-applied topical antimitotic that arrests wart keratinocytes in metaphase and
    causes local tissue necrosis of external anogenital warts.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: podophyllotoxin
      term:
        id: CHEBI:50305
        label: podophyllotoxin
  target_mechanisms:
  - target: Productive Life Cycle Coupled to Keratinocyte Differentiation
    treatment_effect: INHIBITS
    description: >-
      Antimitotic metaphase arrest and necrosis of the productively infected, proliferating
      wart keratinocytes. The agent clears the visible lesion but does not eradicate the
      basal-layer reservoir, so recurrence can follow.
  target_phenotypes:
  - preferred_term: Anogenital warts
    term:
      id: HP:0032301
      label: Genital warts
  evidence:
  - reference: PMID:31675442
    reference_title: "Topically applied treatments for external genital warts in nonimmunocompromised patients: a systematic review and network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "podophyllotoxin 0·5% solution (odds ratio 1·94, 95% confidence interval 1·02-3·71) was significantly more efficacious than imiquimod 5% cream for lesion clearance"
    explanation: >-
      Network meta-analysis found podophyllotoxin 0.5% significantly more efficacious than
      imiquimod 5% cream for external genital wart lesion clearance.

- name: Sinecatechins
  description: >-
    Topical green-tea (Camellia sinensis) catechin extract, standardized on
    epigallocatechin gallate, applied to external anogenital warts; immunostimulatory and
    antiproliferative.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: epigallocatechin gallate
      term:
        id: CHEBI:4806
        label: (-)-epigallocatechin 3-gallate
  target_mechanisms:
  - target: Productive Life Cycle Coupled to Keratinocyte Differentiation
    treatment_effect: MODULATES
    description: >-
      Green-tea catechins exert antiproliferative and immunostimulatory effects on the
      productively infected wart epithelium, promoting clearance of the lesion.
  target_phenotypes:
  - preferred_term: Anogenital warts
    term:
      id: HP:0032301
      label: Genital warts
  evidence:
  - reference: PMID:19709100
    reference_title: "Polyphenon E: a new treatment for external anogenital warts."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Polyphenon E ointment is effective and well tolerated in the treatment of EGWs."
    explanation: >-
      Phase III trial data that sinecatechins (Polyphenon E) ointment effectively clears
      external genital warts.
  - reference: PMID:19709100
    reference_title: "Polyphenon E: a new treatment for external anogenital warts."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Green tea catechins have been identified for their immunostimulatory, antiproliferative and antitumour properties."
    explanation: >-
      Supports the immunostimulatory/antiproliferative mechanism attributed to the green-tea
      catechin extract.

- name: Trichloroacetic acid
  description: >-
    Provider-applied caustic agent that chemically coagulates and destroys wart tissue;
    suitable for external and mucosal anogenital warts including in pregnancy.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: trichloroacetic acid
      term:
        id: CHEBI:30956
        label: trichloroacetic acid
  target_mechanisms:
  - target: Productive Life Cycle Coupled to Keratinocyte Differentiation
    treatment_effect: INHIBITS
    description: >-
      Chemical coagulation and destruction of the productively infected wart tissue;
      lesion-directed cytodestruction that does not clear the basal reservoir.
  target_phenotypes:
  - preferred_term: Anogenital warts
    term:
      id: HP:0032301
      label: Genital warts
  evidence:
  - reference: PMID:39194148
    reference_title: "Successful combination therapy of trichloroacetic acid, podophyllin, and electrocautery on giant condylomata acuminata."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Combination therapy of TCA and podophyllin leads to complete wart clearance"
    explanation: >-
      Case-report evidence that provider-applied trichloroacetic acid contributes to
      clearance of anogenital (condylomata acuminata) warts.

- name: Cryotherapy
  description: >-
    Provider-applied cryosurgery with liquid nitrogen produces cytolytic freezing of wart
    tissue; a first-line ablative option for cutaneous and anogenital warts, usable in
    pregnancy.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: cryosurgery
    term:
      id: NCIT:C15215
      label: Cryosurgery
  target_mechanisms:
  - target: Productive Life Cycle Coupled to Keratinocyte Differentiation
    treatment_effect: INHIBITS
    description: >-
      Cytolytic freezing destroys the productively infected lesion; because the basal-layer
      reservoir may persist, warts can recur after ablation.
  target_phenotypes:
  - preferred_term: Anogenital warts
    term:
      id: HP:0032301
      label: Genital warts
  - preferred_term: Cutaneous warts (verrucae)
    term:
      id: HP:0200043
      label: Verrucae
  evidence:
  - reference: PMID:33433720
    reference_title: "Cryotherapy plus low-dose oral isotretinoin vs cryotherapy only for the treatment of anogenital warts: a randomized clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cryotherapy is a first-line treatment."
    explanation: >-
      Randomized-trial report identifying cryotherapy as a first-line ablative treatment
      for anogenital warts.

- name: Surgical/Ablative Removal
  description: >-
    Physical removal of warts by surgical excision, electrosurgery, curettage, or laser
    ablation; used for large, extensive, or refractory lesions and for recurrent respiratory
    papillomatosis debulking.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  target_mechanisms:
  - target: Productive Life Cycle Coupled to Keratinocyte Differentiation
    treatment_effect: INHIBITS
    description: >-
      Physical removal or ablation of papillomatous lesions (including repeated laser
      debulking in recurrent respiratory papillomatosis) reduces disease burden but does not
      eradicate latent basal-layer infection, so recurrence is common.
  target_phenotypes:
  - preferred_term: Anogenital warts
    term:
      id: HP:0032301
      label: Genital warts
  - preferred_term: Laryngeal papillomatosis
    term:
      id: HP:0033001
      label: Laryngeal papilloma
  evidence:
  - reference: PMID:40143250
    reference_title: "Therapeutic Impact of Gardasil in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is more aggressive in younger patients, necessitating frequent surgical interventions."
    explanation: >-
      Documents that recurrent respiratory papillomatosis requires frequent surgical
      (laser-ablative) interventions to debulk airway papillomas.

📚

References & Deep Research

Deep Research

Falcon ▸

1. Disease Information

Edison Scientific Literature 62 citations 2026-07-01T03:00:53.273477

1. Disease Information

Overview

Human papillomavirus (HPV) is a non-enveloped, double-stranded circular DNA virus belonging to the family Papillomaviridae, with a genome of approximately 8 kilobases (jain2023epidemiologymolecularpathogenesis pages 3-5). It is the most common sexually transmitted viral infection globally, with over 400 identified types and more than 200 characterized variants (wu2024unveilingthemultifaceted pages 1-2, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2). HPV causes approximately 5% of all human cancers worldwide and is implicated in virtually all cervical cancers (99.7%), as well as substantial proportions of anal (71–90%), vaginal (65–74%), vulvar (43–74%), penile (43–63%), and oropharyngeal (10–70%) cancers (mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2). Over 80% of sexually active individuals will contract HPV by age 45, though approximately 90% of infections resolve spontaneously within two years (baba2025humanpapillomavirus pages 1-2).

Key Identifiers and Synonyms

The following table summarizes key disease identifiers, classification schemes, and terminology for HPV infection:

Identifier Type	Value/Code	Description
MONDO ID	MONDO:0005161	Human papilloma virus infection; disease ontology identifier used in aggregated disease knowledge resources and Open Targets disease-target associations (OpenTargets Search: human papillomavirus infectious disease,cervical carcinoma)
ICD-10	B97.7	Papillomavirus as the cause of diseases classified elsewhere; used when HPV is the etiologic infectious agent rather than the primary lesion diagnosis (OpenTargets Search: human papillomavirus infectious disease,cervical carcinoma)
ICD-10	A63.0	Anogenital (venereal) warts / condylomata acuminata; typically caused by low-risk HPV, especially types 6 and 11 (maghiar2024skinlesionscaused pages 4-6, branda2024humanpapillomavirus(hpv) pages 7-9)
ICD-10	B07	Viral warts; includes common cutaneous wart presentations caused by cutaneous HPV types (maghiar2024skinlesionscaused pages 4-6, maghiar2024skinlesionscaused pages 2-4)
ICD-11	1F9	Viral infections characterized by skin and mucous membrane lesions; parent infectious-disease grouping under which HPV-related wart disorders are classified in ICD-11 usage contexts (maghiar2024skinlesionscaused pages 4-6)
ICD-11	1F9Y / specific child codes	Other specified viral infections of skin or mucosa may be used depending on lesion site; HPV-associated neoplasia is coded separately by cancer site (e.g., cervix, anus, oropharynx) rather than by HPV alone (branda2024humanpapillomavirus(hpv) pages 7-9, baba2025humanpapillomavirus pages 10-11)
MeSH	D030361	Papillomavirus Infections; MeSH disease heading for indexing biomedical literature on HPV infection and related manifestations (OpenTargets Search: human papillomavirus infectious disease,cervical carcinoma)
Common synonyms	HPV infection	Standard clinical shorthand for infection with human papillomavirus; most common contemporary synonym (jain2023epidemiologymolecularpathogenesis pages 2-3, malik2023trackinghpvinfection pages 1-2)
Common synonyms	Human papillomavirus infection	Expanded formal disease name used in reviews and public-health literature (wu2024unveilingthemultifaceted pages 1-2, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2)
Common synonyms	Papillomavirus infection	Broader synonym used in classification/pathogenesis literature; may require context to distinguish human from animal papillomavirus infection (mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2, bette2024cottontailrabbitpapillomavirus pages 1-2)
Common synonyms	Condylomata acuminata	Synonym for anogenital warts, a common low-risk HPV manifestation (maghiar2024skinlesionscaused pages 4-6, branda2024humanpapillomavirus(hpv) pages 7-9)
HPV risk classification	High-risk (oncogenic) types	High-risk mucosal types include HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68; these are linked to cervical, anal, penile, vulvar, vaginal, and oropharyngeal cancers. HPV16 and HPV18 account for most cervical cancers (jain2023epidemiologymolecularpathogenesis pages 2-3, pavelescu2025molecularinsightsinto pages 2-4, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2, jain2023epidemiologymolecularpathogenesis pages 3-5)
HPV risk classification	Low-risk types	Low-risk types include HPV6 and HPV11, with additional low-risk mucosal types such as 40, 42, 43, 44, 54, 61, 72, 81, 89; these mainly cause benign lesions such as genital warts and respiratory papillomas (wu2024unveilingthemultifaceted pages 1-2, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2, maghiar2024skinlesionscaused pages 4-6)
Taxonomic classification	Alpha papillomavirus	Predominantly infects genital and oral mucosa; includes both low-risk and high-risk mucosal HPV types associated with anogenital lesions and many HPV-related cancers (wu2024unveilingthemultifaceted pages 1-2, jain2023epidemiologymolecularpathogenesis pages 3-5)
Taxonomic classification	Beta papillomavirus	Primarily cutaneous; commonly found on skin and implicated in some non-melanoma skin cancers, especially in immunocompromised hosts (wu2024unveilingthemultifaceted pages 1-2, bette2024cottontailrabbitpapillomavirus pages 2-3)
Taxonomic classification	Gamma papillomavirus	Primarily associated with cutaneous infection and skin tropism (wu2024unveilingthemultifaceted pages 1-2)
Taxonomic classification	Mu papillomavirus	Cutaneous genus associated with skin wart phenotypes (wu2024unveilingthemultifaceted pages 1-2)
Taxonomic classification	Nu papillomavirus	Cutaneous genus associated with skin wart phenotypes (wu2024unveilingthemultifaceted pages 1-2)

Table: This table summarizes key disease identifiers and classification schemes for human papillomavirus infection, including ontology and coding systems, common synonyms, oncogenic risk groupings, and viral genera. It is useful as a compact reference for mapping HPV across clinical coding, biomedical indexing, and biological classification systems.

Common Synonyms: HPV infection, human papillomavirus infection, papillomavirus infection, condylomata acuminata (for anogenital warts), genital warts, venereal warts, verruca vulgaris (common warts).

2. Etiology

Disease Causal Factors

HPV infection is caused by infection with human papillomavirus, a DNA virus transmitted primarily through direct contact with infected skin or mucous membranes, most commonly via sexual contact (maghiar2024skinlesionscaused pages 2-4). The virus targets basal epithelial cells and enters through microabrasions or disruptions in the epithelial barrier (jain2023epidemiologymolecularpathogenesis pages 3-5). Non-sexual transmission routes include perinatal transmission and autoinoculation (jain2023epidemiologymolecularpathogenesis pages 3-5).

Risk Factors

Environmental and Behavioral Risk Factors: - Multiple sexual partners and early onset of sexual activity (peak infection in teens and twenties) (jain2023epidemiologymolecularpathogenesis pages 2-3, pavelescu2025molecularinsightsinto pages 2-4) - High parity and early pregnancy (pavelescu2025molecularinsightsinto pages 2-4) - Long-term oral contraceptive use (pavelescu2025molecularinsightsinto pages 2-4) - Tobacco smoking and tobacco chewing (pavelescu2025molecularinsightsinto pages 2-4) - Concurrent sexually transmitted infections, particularly HIV (jain2023epidemiologymolecularpathogenesis pages 2-3) - Immunosuppression (baba2025humanpapillomavirus pages 1-2) - Male homosexuality (HPV anal infection prevalence ≥90% in homosexual and HIV-infected men) (jain2023epidemiologymolecularpathogenesis pages 2-3)

Host Genetic Risk Factors: Heritability estimates for cervical carcinoma liability range from 27–29% (olokede2026areviewon pages 6-7). Genome-wide association studies (GWAS) have identified HLA class II loci, particularly HLA-DRB1 and HLA-DQB1, as the strongest genetic determinants of HPV persistence and cervical cancer susceptibility (olokede2026areviewon pages 6-7, olokede2026areviewon pages 1-2). Specific risk alleles include HLA-DRB115:01, HLA-DQB106:02, HLA-DRB113:02, HLA-DQB105:02, and HLA-DRB1*03:01 (olokede2026areviewon pages 6-7, pavelescu2025molecularinsightsinto pages 11-13). Additional GWAS loci outside the MHC region include GSDMB (pyroptosis regulation), MUC1 (mucosal barrier), DSG2/CDH1 (epithelial adhesion), and TFAP2A (differentiation pathway) (olokede2026areviewon pages 16-17).

Protective Factors

Genetic Protective Factors: HLA-DRB113:01 and HLA-DQB106:03 confer protection through superior binding dynamics for conserved E6/E7 epitopes, facilitating robust Th1 immune responses (olokede2026areviewon pages 6-7). HLA-DRB115:03 was associated with decreased risk of persistent high-risk HPV (olokede2026areviewon pages 6-7). Notably, DRB11302-positive women had significantly lower cumulative progression rates to CIN3 (2.1% vs 14.0%) over 10 years (li2025biomarkersdifferentiatingregression pages 8-9).

Environmental Protective Factors: - HPV vaccination (most effective preventive measure) (wu2024unveilingthemultifaceted pages 9-10) - Consistent condom use and limiting sexual partners (wu2024unveilingthemultifaceted pages 9-10) - Male circumcision (uncircumcised men have greater genital mucosa exposure) (baba2025humanpapillomavirus pages 10-11)

Gene-Environment Interactions

DNA repair capacity variants interact with tobacco smoke mutagens to influence HPV-driven carcinogenesis, and estrogen receptor polymorphisms (ESR1 PvuII and XbaI variants) interact with exogenous steroid hormones to upregulate viral E6/E7 oncogenes (olokede2026areviewon pages 19-21). Progesterone signaling upregulates DNA methyltransferases (DNMT1, DNMT3B) to promote hypermethylation of tumor suppressor genes (olokede2026areviewon pages 19-21). Vaginal dysbiosis and mucosal barrier dynamics represent additional relevant gene-environment interaction factors (olokede2026areviewon pages 19-21).

3. Phenotypes

Clinical Manifestations

Cutaneous Warts: - Common warts (verruca vulgaris), plantar warts, flat warts - Cutaneous warts affect 7–12% of the population, with higher prevalence in children and adolescents (10–20% annual incidence) (maghiar2024skinlesionscaused pages 2-4) - HPO terms: HP:0200043 (Verrucae), HP:0010283 (Verruca plana)

Anogenital Warts (Condylomata Acuminata): - Caused primarily by HPV types 6 and 11 (branda2024humanpapillomavirus(hpv) pages 7-9) - Develop several months after infection; often asymptomatic but may cause itching and bleeding (branda2024humanpapillomavirus(hpv) pages 7-9) - HPO terms: HP:0030799 (Condylomata acuminata)

Cervical Intraepithelial Neoplasia (CIN): - CIN1: reflects transient infection, low-grade squamous intraepithelial lesion (LSIL) (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2) - CIN2: variable malignant potential, intermediate-grade lesion (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2, li2025biomarkersdifferentiatingregression pages 6-7) - CIN3: most significant precursor to invasive cervical cancer (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2) - HPO terms: HP:0032260 (Cervical intraepithelial neoplasia)

HPV-Associated Cancers: - Cervical cancer (virtually all cases HPV-attributable; HPV16 accounts for 55%, HPV18 for 15%) (jain2023epidemiologymolecularpathogenesis pages 3-5) - Oropharyngeal squamous cell carcinoma (rising rapidly in developed countries) (baba2025humanpapillomavirus pages 1-2) - Anal cancer (90% HPV-attributable) (mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2) - Penile, vulvar, and vaginal cancers (baba2025humanpapillomavirus pages 1-2) - HPO terms: HP:0012126 (Cervical squamous cell carcinoma), HP:0100649 (Neoplasm of the oral cavity)

Quality of Life Impact: HPV-associated cancers impose significant morbidity and mortality. In 2020, cervical cancer alone accounted for 604,127 new cases and 341,831 deaths globally, making it the second most common cancer in women aged 15–44 (jain2023epidemiologymolecularpathogenesis pages 2-3).

4. Genetic/Molecular Information

Viral Genome Structure

The HPV genome (~8 kb) consists of early genes (E1, E2, E4, E5, E6, E7) and late genes (L1, L2) (jain2023epidemiologymolecularpathogenesis pages 3-5, bette2024cottontailrabbitpapillomavirus pages 2-3). The early gene products control viral replication, transcription regulation, and cellular transformation, while L1 and L2 encode the viral capsid proteins.

Oncoproteins and Molecular Mechanisms

The following table summarizes the key molecular mechanisms of HPV oncoproteins:

Viral Protein	Host Target	Mechanism	Signaling Pathway	Biological Consequence
E6	TP53 (p53) via E6AP/UBE3A	Forms E6–E6AP complex that ubiquitinates and degrades p53	p53/cell-cycle checkpoint, apoptosis	Loss of G1/S arrest, impaired DNA-damage response, reduced apoptosis, mutation accumulation (martinelli2025molecularmechanismsand pages 4-5, wu2024unveilingthemultifaceted pages 2-3, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 10-11, baba2025humanpapillomavirus pages 4-6)
E6	hTERT promoter/telomerase machinery	Induces hTERT expression and telomerase activation	Telomere maintenance/immortalization	Cellular immortalization and prolonged survival of infected cells (wu2024unveilingthemultifaceted pages 2-3, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 10-11, kao2026theroleof pages 3-5)
E6	PTEN/TSC2 and upstream PI3K regulators	Inactivates PTEN and promotes mTOR signaling, enhancing PI3K/AKT activity	PI3K/AKT/mTOR	Increased proliferation, survival, autophagy inhibition, treatment resistance (baba2025humanpapillomavirus pages 6-8, martinelli2025molecularmechanismsand pages 4-5, pavelescu2025molecularinsightsinto pages 8-10)
E6	β-catenin regulatory axis	Stabilizes/activates nuclear β-catenin and oncogenic transcription	Wnt/β-catenin	Upregulation of c-Myc/cyclin D1, enhanced growth and transformation (baba2025humanpapillomavirus pages 6-8, pavelescu2025molecularinsightsinto pages 8-10)
E6	NOTCH1 and associated control of differentiation	Disrupts NOTCH1 signaling and p53-linked differentiation/senescence programs	Notch signaling	Loss of differentiation, escape from senescence, tumor progression (baba2025humanpapillomavirus pages 6-8, martinelli2025molecularmechanismsand pages 4-5, pavelescu2025molecularinsightsinto pages 8-10)
E7	RB1 (pRb) via LXCXE motif	Binds pocket proteins and promotes pRb degradation/inactivation	pRb/E2F cell-cycle control	Unchecked G1-to-S progression and viral/cellular DNA synthesis (martinelli2025molecularmechanismsand pages 4-5, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 10-11, baba2025humanpapillomavirus pages 4-6)
E7	E2F transcription factors	Releases E2F after pRb inactivation	E2F-driven transcription	Increased S-phase entry, replication gene expression, uncontrolled proliferation (martinelli2025molecularmechanismsand pages 4-5, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 10-11, baba2025humanpapillomavirus pages 4-6)
E7	Centrosome duplication machinery	Perturbs centrosome control and mitotic fidelity	Chromosomal stability/mitotic control	Aneuploidy, chromosomal instability, invasive transformation (martinelli2025molecularmechanismsand pages 5-7)
E5	EGFR	Enhances EGFR signaling and downstream kinase activation	EGFR/MAPK/ERK, PI3K/AKT	Increased proliferation, survival, migration, oncogene induction (including c-Fos) (baba2025humanpapillomavirus pages 6-8, vallejoruiz2024molecularaspectsof pages 2-3, pavelescu2025molecularinsightsinto pages 8-10)
E5	MHC-I trafficking machinery	Retains MHC-I in ER/Golgi and reduces surface antigen presentation	Antigen presentation/immune evasion	Reduced CD8+ T-cell recognition and viral persistence (baba2025humanpapillomavirus pages 6-8, vallejoruiz2024molecularaspectsof pages 2-3)
E5	STING (TMEM173) innate sensing pathway	Interferes with STING signaling and downstream interferon induction	cGAS–STING / innate antiviral response	Blunted interferon response and enhanced immune escape/persistence (vallejoruiz2024molecularaspectsof pages 2-3)
APOBEC3B induction in HPV-driven cells	Host genomic DNA (cytidines), linked to E6-driven dysregulation	Cytidine deamination produces APOBEC mutational signatures and hotspot mutations	APOBEC mutagenesis / genomic instability	C→T transition burden, oncogenic mutations (e.g., PIK3CA hotspots), malignant progression (janiszewska2025hpvdrivenoncogenesis—muchmore pages 3-4, janiszewska2025hpvdrivenoncogenesis—muchmore pages 4-6)

Table: This table summarizes the major HPV molecular mechanisms most relevant to persistence, immune evasion, and carcinogenesis. It highlights how E5, E6, E7, and APOBEC-associated processes map onto host targets and signaling pathways.

E6 Oncoprotein: E6 forms a complex with E6-associated protein (E6AP/UBE3A), an E3 ubiquitin ligase, to target p53 for proteasomal degradation, eliminating G1/S checkpoint control and DNA damage response (wu2024unveilingthemultifaceted pages 2-3, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 10-11, baba2025humanpapillomavirus pages 4-6). E6 additionally induces hTERT expression for cellular immortalization, activates PI3K/AKT/mTOR signaling (inhibiting autophagy and promoting proliferation), stabilizes Wnt/β-catenin signaling (upregulating c-Myc and cyclin D1), and disrupts Notch1 signaling (baba2025humanpapillomavirus pages 6-8, pavelescu2025molecularinsightsinto pages 8-10). E6 also inhibits extrinsic apoptosis by interacting with FADD and caspase-8 and suppresses IRF-3 to diminish immune responses (wu2024unveilingthemultifaceted pages 2-3).

E7 Oncoprotein: E7 binds retinoblastoma protein (pRb) and related pocket proteins (p107, p130) through the LXCXE binding motif, causing their ubiquitination and proteasomal degradation (baba2025humanpapillomavirus pages 4-6). This releases E2F transcription factors, driving S-phase cell cycle progression (martinelli2025molecularmechanismsand pages 4-5, baba2025humanpapillomavirus pages 4-6). E7 also disrupts centrosome duplication leading to chromosomal instability, activates DNA methyltransferases causing aberrant epigenetic modifications, and modulates STAT1, NF-κB, IRF1, and SMAD2/3 transcription factors (martinelli2025molecularmechanismsand pages 4-5, martinelli2025molecularmechanismsand pages 5-7).

E5 Oncoprotein: E5 enhances EGFR signaling to activate MAPK/ERK and PI3K/AKT pathways, promoting proliferation and survival (baba2025humanpapillomavirus pages 6-8, vallejoruiz2024molecularaspectsof pages 2-3). E5 mediates immune evasion by retaining MHC-I molecules in the ER/Golgi, reducing antigen presentation, and by interfering with STING signaling to suppress interferon responses (vallejoruiz2024molecularaspectsof pages 2-3).

Viral Integration and Genomic Instability

HPV integration into the host genome occurs in 70–85% of HPV-positive cancers and represents a critical transition from infection to malignancy (martinelli2025molecularmechanismsand pages 5-7). Integration typically disrupts the E2 gene, removing its suppressive effect on E6/E7 expression and allowing unrestricted oncoprotein activity (kao2026theroleof pages 3-5, janiszewska2025hpvdrivenoncogenesis—muchmore pages 1-3). Integration occurs at fragile sites in the host genome and causes direct genomic instability through disruption of tumor suppressor genes and upregulation of oncogenes (janiszewska2025hpvdrivenoncogenesis—muchmore pages 3-4, martinelli2025molecularmechanismsand pages 5-7).

APOBEC Mutagenesis

A recently characterized non-canonical mechanism involves APOBEC3B enzymes, which are activated by interferon-mediated immune responses to viral nucleic acids. These enzymes mediate cytidine deamination, generating C→T transition mutations in the host genome that promote malignant transformation (janiszewska2025hpvdrivenoncogenesis—muchmore pages 3-4). E6 oncoprotein expression drives APOBEC3B overexpression through TP53 degradation and TEAD transcription factor activation. APOBEC has been identified as the dominant mutational signature in HPV16+ oropharyngeal cancers, with direct links to oncogenic mutations such as PIK3CA E542K/E545K hotspots (janiszewska2025hpvdrivenoncogenesis—muchmore pages 3-4, janiszewska2025hpvdrivenoncogenesis—muchmore pages 4-6).

HPV-Derived miRNAs

Five putative HPV16-encoded miRNAs (miR-H1, H2, H3, H5, H6) have been identified, showing low-level expression in cervical lesions (janiszewska2025hpvdrivenoncogenesis—muchmore pages 4-6). These may contribute to immune escape, cell cycle deregulation, and tumor suppressor attenuation, though significant inconsistencies exist between research groups regarding their targets and functional significance (janiszewska2025hpvdrivenoncogenesis—muchmore pages 6-7, janiszewska2025hpvdrivenoncogenesis—muchmore pages 4-6).

Epigenetic Changes

DNA methylation represents one of the earliest and most clinically informative epigenetic alterations in HPV-driven carcinogenesis (legaki2026hpvdrivencervicalcarcinogenesis pages 4-5). E7 activates DNA methyltransferases causing aberrant hypermethylation of tumor suppressor genes including CDKN2A and CDH1 (olokede2026areviewon pages 16-17, baba2025humanpapillomavirus pages 4-6). Host gene methylation biomarkers including FAM19A4, CADM1, PAX1, and MAL show promise for detecting high-grade intraepithelial lesions (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2, li2025biomarkersdifferentiatingregression pages 8-9). DNMT3B polymorphisms (-149C>T) promote hypermethylation of tumor suppressors (olokede2026areviewon pages 16-17).

5. Environmental Information and Infectious Agent

Infectious Agent

Pathogen: Human papillomavirus (HPV), Family Papillomaviridae, small non-enveloped DNA virus (NCBI Taxonomy ID: 10566 for HPV16)

HPV is classified into five genera (alpha, beta, gamma, mu, nu), with the alpha genus being most clinically significant for mucosal infections and malignancies (wu2024unveilingthemultifaceted pages 1-2). At least 14 high-risk types (Group 1 carcinogens per IARC) are recognized: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 (pavelescu2025molecularinsightsinto pages 2-4). HPV is resistant to many disinfectants and relatively unsusceptible to external conditions (mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2).

Lifestyle and Environmental Cofactors

Tobacco smoking, UV radiation exposure (particularly for beta-HPV-associated cutaneous malignancies), long-term hormonal contraceptive use, and high parity act as cofactors that augment HPV-driven carcinogenesis (pavelescu2025molecularinsightsinto pages 2-4).

6. Mechanism / Pathophysiology

Causal Chain: From Infection to Cancer

Initial Infection: HPV gains access to basal epithelial cells through microabrasions in stratified squamous epithelium (jain2023epidemiologymolecularpathogenesis pages 3-5)
Viral Establishment: The virus establishes episomal infection in basal cells, maintaining low copy numbers and utilizing host DNA replication machinery (jain2023epidemiologymolecularpathogenesis pages 3-5)
Immune Evasion: E5 downregulates MHC-I/II and inhibits STING-interferon signaling; E6 suppresses IRF-3; E7 suppresses RIG-I and cGAS-STING pathways (baba2025humanpapillomavirus pages 6-8, vallejoruiz2024molecularaspectsof pages 2-3)
Viral Persistence: In 10–20% of infected women, immune evasion enables chronic infection lasting years (jain2023epidemiologymolecularpathogenesis pages 2-3)
Genomic Integration: Viral DNA integrates into host genome at fragile sites (70–85% of HPV+ cancers), disrupting E2 and unleashing constitutive E6/E7 expression (martinelli2025molecularmechanismsand pages 5-7)
Cellular Transformation: E6-mediated p53 degradation and E7-mediated pRb inactivation abolish cell cycle checkpoints, while APOBEC mutagenesis generates somatic mutations (wu2024unveilingthemultifaceted pages 2-3, baba2025humanpapillomavirus pages 4-6, janiszewska2025hpvdrivenoncogenesis—muchmore pages 3-4)
Malignant Progression: Accumulated genetic and epigenetic alterations, chromosomal instability, and immune microenvironment remodeling drive progression from CIN to invasive carcinoma (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2, martinelli2025molecularmechanismsand pages 5-7)

Key Signaling Pathways

p53/apoptosis pathway (GO:0006915 apoptotic process): E6-mediated p53 degradation
pRb/E2F/cell cycle (GO:0007049 cell cycle): E7-mediated pRb inactivation
PI3K/AKT/mTOR (GO:0043491): E6/E7 activation promoting proliferation
Wnt/β-catenin (GO:0060070): E6-mediated β-catenin stabilization
MAPK/ERK (GO:0000165): E5-mediated EGFR activation
cGAS-STING/interferon (GO:0032481): E5-mediated immune suppression
DNA damage response (GO:0006281): E6/E7 hijacking of ATM/ATR, BRCA1, RAD51 (martinelli2025molecularmechanismsand pages 17-18, kao2026theroleof pages 3-5)

Cell Types Involved

Basal keratinocytes (CL:0000312): Primary target cells for HPV infection
Cervical epithelial cells (CL:0002535): Site of cervical carcinogenesis
CD4+ T helper cells (CL:0000492): Critical for HPV clearance; modulated by HLA-mediated antigen presentation
CD8+ cytotoxic T cells (CL:0000794): Effector cells for eliminating HPV-infected cells

7. Anatomical Structures Affected

Organ Level

Primary organs: Uterine cervix (UBERON:0000002), oropharynx (UBERON:0001729), anus (UBERON:0001245), vulva, vagina, penis
Secondary involvement: Regional lymph nodes (metastatic spread), respiratory tract (laryngeal papillomatosis)
Body systems: Reproductive system, integumentary system, upper aerodigestive tract

Tissue and Cell Level

Tissues affected: Stratified squamous epithelium (mucosal and cutaneous), transformation zone of cervix
Specific cell populations: Basal epithelial cells (primary viral targets), squamous epithelial cells at various differentiation stages

Localization

HPV infection sites correspond to virus-epithelium tropism. Alpha-HPV types predominantly affect anogenital and oropharyngeal mucosal epithelium, while beta, gamma, mu, and nu types primarily affect cutaneous epithelium (wu2024unveilingthemultifaceted pages 1-2). HPV-associated lesions can be bilateral and multifocal.

8. Temporal Development

Onset

Age of acquisition: Peak incidence in sexually active teens and young adults (jain2023epidemiologymolecularpathogenesis pages 2-3)
Onset pattern: Typically insidious; infection is usually asymptomatic, with clinical manifestations developing weeks to years after exposure (branda2024humanpapillomavirus(hpv) pages 7-9)

Progression

Natural history: Most infections (approximately 90%) resolve spontaneously within 1–2 years through immune clearance (baba2025humanpapillomavirus pages 1-2). Persistent infection with high-risk types over years to decades may progress through CIN1 → CIN2 → CIN3 → invasive carcinoma (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2)
Disease duration: Self-limited in most cases; chronic lifelong in persistent infections
Critical period: The interval between persistent high-risk HPV infection and invasive cancer development typically spans 10–20 years, providing a window for screening and intervention

9. Inheritance and Population

Epidemiology

Global prevalence: Approximately 291 million women worldwide carry HPV; estimated 79 million Americans currently infected (pavelescu2025molecularinsightsinto pages 2-4, maghiar2024skinlesionscaused pages 2-4)
Incidence: Approximately 14 million new infections annually in the U.S.; globally, HPV causes approximately 610,000 cancer cases and over 250,000 deaths annually (maghiar2024skinlesionscaused pages 2-4, wu2024unveilingthemultifaceted pages 1-2)
Geographic variation: HPV prevalence is significantly higher in developing regions (42.2%) compared to developed regions (22.6%), with particularly high rates in Sub-Saharan Africa (24%), Latin America, and parts of Asia (jain2023epidemiologymolecularpathogenesis pages 2-3). In 2020, cervical cancer had 604,127 new cases and 341,831 deaths globally (jain2023epidemiologymolecularpathogenesis pages 2-3)

Host Genetic Architecture

While HPV infection itself is infectious (not inherited), host genetic susceptibility to persistent infection and cancer development follows a polygenic architecture, with heritability estimates of 27–29% for cervical carcinoma liability (olokede2026areviewon pages 6-7). HLA allele frequencies vary dramatically across geographic ancestries, with protective alleles more prevalent in European populations but absent in sub-Saharan African cohorts where cervical cancer burden is highest (olokede2026areviewon pages 6-7).

Population Demographics

Sex ratio: Both sexes affected; 85% of women and 95% of sexually active men are infected at some point (jain2023epidemiologymolecularpathogenesis pages 2-3)
Age distribution: Bimodal age distribution for HPV prevalence in women, with peaks in young adults and women aged 45+ (pavelescu2025molecularinsightsinto pages 2-4)

10. Diagnostics

Clinical Tests

Papanicolaou (Pap) smear: Cytological screening that detects LSIL/HSIL; has significantly reduced cervical cancer incidence but has limited sensitivity (baba2025humanpapillomavirus pages 10-11, wu2024unveilingthemultifaceted pages 9-10)
HPV DNA testing: Detects high-risk HPV nucleic acids via PCR; more accurate and objective than cytology; WHO-endorsed as preferred cervical cancer screening strategy (maghiar2024skinlesionscaused pages 4-6, maghiar2024skinlesionscaused pages 6-7)
HPV mRNA PCR: Reflects active viral transcription and provides prognostic information (baba2025humanpapillomavirus pages 10-11)
Colposcopy: Non-invasive examination using 3–5% acetic acid to identify acetowhite changes and abnormal vascular patterns (branda2024humanpapillomavirus(hpv) pages 7-9)
Visual inspection with acetic acid (VIA): Low-cost screening approach for resource-limited settings (jain2023epidemiologymolecularpathogenesis pages 10-12)
Biopsy and histopathology: Tissue analysis showing papillomatosis, hypergranulosis, acanthosis, and koilocytosis (karaoglan2024unveilingtherole pages 3-4)
Immunohistochemistry: Detection of HPV capsid proteins; p16ink4a overexpression as surrogate marker of high-risk HPV E7 activity (branda2024humanpapillomavirus(hpv) pages 5-6, karaoglan2024unveilingtherole pages 3-4)
Next-generation sequencing: Highly sensitive detection of low-copy-number types and novel variants (karaoglan2024unveilingtherole pages 3-4)

Biomarkers

p16ink4a/Ki-67 dual staining: Protein biomarkers for high-grade cervical dysplasia detection (branda2024humanpapillomavirus(hpv) pages 5-6)
DNA methylation biomarkers: FAM19A4, CADM1, PAX1, and MAL methylation as promising markers for CIN2+ detection (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2, li2025biomarkersdifferentiatingregression pages 8-9)
E6/E7 mRNA expression: Indicates active viral oncogene transcription (branda2024humanpapillomavirus(hpv) pages 5-6)

Self-Sampling

Modern guidelines, including 2025 ASCCP recommendations, advocate for self-collected vaginal samples for high-risk HPV testing to improve screening accessibility, with WHO targeting 70% of women screened by 2030 (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2, maghiar2024skinlesionscaused pages 6-7).

11. Outcome/Prognosis

Survival and Mortality

Most HPV infections are self-limited, with ~90% clearing within 2 years (baba2025humanpapillomavirus pages 1-2)
10–20% of infected women develop persistent infection with potential for malignant progression (jain2023epidemiologymolecularpathogenesis pages 2-3)
Cervical cancer: 604,127 new cases and 341,831 deaths globally in 2020 (jain2023epidemiologymolecularpathogenesis pages 2-3)
HPV-positive oropharyngeal cancer patients demonstrate better clinical prognosis and heightened radiosensitivity compared to HPV-negative counterparts (martinelli2025molecularmechanismsand pages 4-5)
Approximately 47,200 new HPV-associated cancer cases occur annually in the U.S. (malik2023trackinghpvinfection pages 1-2)

Prognostic Biomarkers

HPV genotype (HPV16/18 vs. other high-risk types) (li2025biomarkersdifferentiatingregression pages 6-7)
HLA alleles: DRB1*1302-positive women had significantly lower cumulative CIN3 progression rates (2.1% vs 14.0% over 10 years) (li2025biomarkersdifferentiatingregression pages 8-9)
DNA methylation patterns (FAM19A4, miR-124-2, EPB41L3) for CIN2 regression/progression prediction (li2025biomarkersdifferentiatingregression pages 8-9)
p16/Ki-67 status for CIN2 outcome prediction (li2025biomarkersdifferentiatingregression pages 6-7)

12. Treatment

The following table provides a comprehensive overview of current and emerging HPV treatment and prevention approaches:

Category	Intervention	Mechanism/Description	Evidence Level
Physical treatment	Cryotherapy	Liquid nitrogen freezing destroys visible HPV-associated lesions such as warts; commonly used office-based ablative treatment (jain2023epidemiologymolecularpathogenesis pages 12-13, maghiar2024skinlesionscaused pages 6-7)	Established clinical practice / guideline-supported review evidence
Physical treatment	LEEP	Loop electrosurgical excision procedure removes cervical transformation-zone tissue and is used for treatment of high-grade cervical intraepithelial lesions (jain2023epidemiologymolecularpathogenesis pages 12-13)	Established clinical practice / guideline-supported review evidence
Physical treatment	Electrocautery	Thermal destruction/removal of wart tissue or dysplastic lesions; used for anogenital and cutaneous lesions (jain2023epidemiologymolecularpathogenesis pages 12-13, maghiar2024skinlesionscaused pages 6-7)	Established clinical practice / review evidence
Physical treatment	Laser therapy	CO2 or related laser ablation for extensive, refractory, or anatomically difficult lesions (jain2023epidemiologymolecularpathogenesis pages 12-13, maghiar2024skinlesionscaused pages 6-7)	Established clinical practice / review evidence
Physical treatment	Surgical excision	Direct removal of resistant or suspicious lesions; effective but may require anesthesia and can scar (maghiar2024skinlesionscaused pages 7-9, maghiar2024skinlesionscaused pages 6-7)	Established clinical practice / review evidence
Chemical treatment	Salicylic acid	Topical keratolytic that gradually destroys hyperkeratotic wart tissue; requires repeated application (maghiar2024skinlesionscaused pages 7-9, maghiar2024skinlesionscaused pages 6-7)	Established clinical practice / review evidence
Chemical treatment	Cantharidin	Vesicant topical agent that induces blistering and separation of lesion tissue in wart management (maghiar2024skinlesionscaused pages 7-9, maghiar2024skinlesionscaused pages 6-7)	Established clinical practice / review evidence
Immunomodulatory	Imiquimod (TLR7 agonist)	Activates TLR7-mediated innate immune signaling to enhance local antiviral immune response; used particularly for anogenital warts (jain2023epidemiologymolecularpathogenesis pages 12-13, OpenTargets Search: human papillomavirus infectious disease,cervical carcinoma)	Approved targeted therapy / OpenTargets-supported association
Prophylactic vaccine	Cervarix (bivalent)	L1 virus-like particle vaccine targeting HPV16/18 to prevent acquisition of high-risk infection and cervical precancer/cancer (jain2023epidemiologymolecularpathogenesis pages 12-13, wu2024unveilingthemultifaceted pages 9-10, jain2023epidemiologymolecularpathogenesis pages 10-12)	High-level evidence; licensed vaccine
Prophylactic vaccine	Gardasil (quadrivalent)	L1 VLP vaccine targeting HPV6/11/16/18; prevents genital warts and high-risk HPV infection (wu2024unveilingthemultifaceted pages 9-10, jain2023epidemiologymolecularpathogenesis pages 10-12)	High-level evidence; licensed vaccine
Prophylactic vaccine	Gardasil 9 (nonavalent)	Expanded L1 VLP vaccine covering HPV6/11/16/18/31/33/45/52/58; broadest currently licensed prophylactic coverage in many settings (jain2023epidemiologymolecularpathogenesis pages 12-13, wu2024unveilingthemultifaceted pages 9-10, jain2023epidemiologymolecularpathogenesis pages 10-12)	High-level evidence; licensed vaccine
Prophylactic vaccine	Cecolin	Bivalent prophylactic HPV vaccine included among currently available VLP-based vaccines (jain2023epidemiologymolecularpathogenesis pages 10-12)	Licensed/implementation evidence in reviews
Prophylactic vaccine	Cervavax	Quadrivalent prophylactic HPV vaccine included in current vaccine landscape reviews (jain2023epidemiologymolecularpathogenesis pages 12-13, jain2023epidemiologymolecularpathogenesis pages 10-12)	Licensed/implementation evidence in reviews
Therapeutic vaccine	Viral vector-based vaccines	Experimental vaccines deliver HPV antigens, usually E6/E7, via viral vectors to induce cell-mediated clearance of infected/transformed cells (branda2024humanpapillomavirus(hpv) pages 5-6, jain2023epidemiologymolecularpathogenesis pages 22-24)	Early-phase/experimental
Therapeutic vaccine	DNA-based vaccines	Plasmid/DNA immunization strategies encoding HPV antigens aim to generate cytotoxic T-cell responses against established infection or dysplasia (jain2023epidemiologymolecularpathogenesis pages 22-24)	Early-phase/experimental
Chemotherapy	Cisplatin-based combinations	Standard systemic therapy for advanced cervical cancer; combinations with bevacizumab, topotecan, paclitaxel, 5-FU, or bleomycin improve antitumor activity in selected settings (baba2025humanpapillomavirus pages 15-17)	Standard oncology practice / review evidence
Immunotherapy	Pembrolizumab	Immune checkpoint inhibitor targeting PD-1; used in HPV-related cancers, especially recurrent/metastatic cervical cancer and other advanced HPV-driven malignancies (maghiar2024skinlesionscaused pages 7-9, baba2025humanpapillomavirus pages 15-17)	Approved/late-stage oncology evidence
Immunotherapy	Nivolumab	PD-1 checkpoint blockade investigated/used in HPV-associated cancers to restore antitumor T-cell function (baba2025humanpapillomavirus pages 15-17)	Clinical evidence / advanced oncology use
Immunotherapy	Durvalumab	PD-L1 checkpoint inhibitor under study or use in HPV-mediated cancers as immune-restorative therapy (baba2025humanpapillomavirus pages 15-17)	Clinical evidence / advanced oncology use
Advanced therapy	siRNA targeting E6/E7	RNA interference suppresses viral oncogene expression, restoring p53/p21 signaling and inhibiting tumor growth; preclinical LNP-siRNA plus cisplatin data are promising (baba2025humanpapillomavirus pages 15-17)	Preclinical to early translational
Advanced therapy	CRISPR/Cas9 targeting E6/E7	Gene-editing approaches disrupt HPV oncogenes and can trigger tumor cell death or growth arrest in experimental systems (baba2025humanpapillomavirus pages 15-17)	Experimental / preclinical
Screening program	Pap smear (cytology)	Cytologic screening detects LSIL/HSIL and has reduced cervical cancer incidence and mortality where implemented (branda2024humanpapillomavirus(hpv) pages 7-9, baba2025humanpapillomavirus pages 10-11, wu2024unveilingthemultifaceted pages 9-10)	Established population screening
Screening program	HPV DNA testing	Detects high-risk HPV nucleic acids; more accurate/objective than cytology and now preferred by WHO for cervical screening in many settings (maghiar2024skinlesionscaused pages 4-6, jain2023epidemiologymolecularpathogenesis pages 10-12, maghiar2024skinlesionscaused pages 6-7)	High-level evidence; preferred modern screening
Screening program	VIA (visual inspection with acetic acid)	Low-cost screening approach used especially in resource-limited settings to identify acetowhite cervical abnormalities (baba2025humanpapillomavirus pages 10-11, jain2023epidemiologymolecularpathogenesis pages 10-12)	Programmatic/public health screening evidence

Table: This table summarizes major current and emerging approaches to HPV treatment, prevention, and screening, spanning lesion-directed therapies, vaccines, systemic cancer treatments, and population screening tools. It is useful for quickly comparing mechanisms and maturity of evidence across interventions.

Key Therapeutic Targets (OpenTargets)

OpenTargets analysis (MONDO:0005161) identified three primary drug targets for HPV infection: TLR7 (toll-like receptor 7; highest association score 0.53, with approved drug imiquimod), IFNAR1 (interferon alpha/beta receptor subunit 1), and IFNAR2 (interferon alpha/beta receptor subunit 2) (OpenTargets Search: human papillomavirus infectious disease,cervical carcinoma).

Emerging Therapies

siRNA-based approaches: ENB101-LNP, encapsulating siRNA against HPV16 E6/E7, combined with cisplatin showed 68.8% tumor inhibition and up to 80% E6/E7 knockdown in xenograft models (baba2025humanpapillomavirus pages 15-17)
TCR-engineered T-cell therapies: Targeting E7 oncoprotein for adoptive cell therapy (baba2025humanpapillomavirus pages 15-17)
CRISPR/Cas9 gene editing: Targeting E6/E7 genomic sequences to induce tumor cell death (baba2025humanpapillomavirus pages 15-17)
PARP inhibitors: E7-mediated upregulation of miR-182 downregulates BRCA1, potentially sensitizing HPV+ cancers to PARP inhibition (martinelli2025molecularmechanismsand pages 17-18)

Active Clinical Trials

Multiple Phase 3 clinical trials are currently investigating HPV vaccines and treatments, including: - CERVAVAC® quadrivalent HPV vaccine in HIV-positive women aged 15–25 (NCT06281119; 450 participants) - Nonavalent HPV vaccine efficacy trial (NCT05668572; 12,000 participants) - Dose reduction immunobridging studies in African settings (NCT02834637; 930 participants)

MAXO terms: MAXO:0001017 (vaccination), MAXO:0000004 (surgical procedure), MAXO:0010203 (cryotherapy), MAXO:0000647 (chemotherapy)

13. Prevention

Primary Prevention

Vaccination is the most effective primary prevention strategy. Currently licensed prophylactic vaccines include bivalent (Cervarix: HPV16/18), quadrivalent (Gardasil: HPV6/11/16/18), and nonavalent (Gardasil 9: HPV6/11/16/18/31/33/45/52/58) formulations, as well as Cecolin and Cervavax (jain2023epidemiologymolecularpathogenesis pages 12-13, jain2023epidemiologymolecularpathogenesis pages 10-12). In Australia, HPV prevalence dropped from 22.7% pre-vaccination to 1.5% by 2015 (ashique2023hpvpathogenesisvarious pages 2-4). Countries with robust vaccination programs have witnessed 54–83% declines in high-grade cervical abnormalities and genital warts (jain2023epidemiologymolecularpathogenesis pages 12-13). WHO targets 90% of girls vaccinated by age 15 as part of the cervical cancer elimination strategy (jain2023epidemiologymolecularpathogenesis pages 10-12).

Secondary Prevention

Screening programs form the backbone of secondary prevention. HPV DNA testing is now endorsed by WHO as the preferred cervical cancer screening strategy over conventional cytology (maghiar2024skinlesionscaused pages 4-6). The WHO Global Strategy targets screening 70% of women at ages 35 and 45 and ensuring 90% of women with cervical disease receive proper treatment (jain2023epidemiologymolecularpathogenesis pages 10-12). Concomitant HPV vaccination and screening has been proposed for faster cervical cancer elimination (wu2024unveilingthemultifaceted pages 9-10).

Tertiary Prevention

Management of established CIN and HPV-associated cancers through LEEP, surgical excision, chemotherapy, radiation therapy, and immunotherapy (jain2023epidemiologymolecularpathogenesis pages 12-13, baba2025humanpapillomavirus pages 15-17).

14. Other Species / Natural Disease

Taxonomy and Comparative Biology

Papillomaviruses exhibit extremely high host species specificity, infecting various species including fish, reptiles, birds, and vertebrates (bette2024cottontailrabbitpapillomavirus pages 1-2). Due to this species restriction, human HPV types cannot infect animals, and animal papillomaviruses cannot infect humans.

Natural papillomavirus infections in other species: - Cottontail rabbit (Sylvilagus floridanus): CRPV (Cottontail Rabbit Papillomavirus) causes cutaneous papillomas with high oncogenic potential for progression to squamous cell carcinomas, predominantly on the head and neck (bette2024cottontailrabbitpapillomavirus pages 1-2, bette2024cottontailrabbitpapillomavirus pages 3-5) - Domestic rabbit (Oryctolagus cuniculus): Experimentally susceptible to CRPV infection (bette2024cottontailrabbitpapillomavirus pages 1-2) - Canine species: Canine oral papillomavirus causes papillomas; dogs have immune systems more closely resembling human responses (totain2023developmentofhpv16 pages 7-10)

CRPV E7 inhibits retinoblastoma protein similar to HPV E7, but CRPV E6 differs by binding hDlg/SAP97 rather than p53 (bette2024cottontailrabbitpapillomavirus pages 2-3). Rabbit papillomas and carcinomas closely resemble human HPV-induced tumors (bette2024cottontailrabbitpapillomavirus pages 2-3).

15. Model Organisms

Mouse Models

TC-1 cells (C57BL/6): The most commonly used HPV model; C57BL/6 cells expressing HPV16 E6/E7 proteins, used for subcutaneous tumor isograft studies (totain2023developmentofhpv16 pages 1-2). Limitations include restriction to one genetic background and HPV16-only studies.
K14-HPV16 transgenic mice: Express E7 constitutively in skin under keratin 14 promoter; develop immune tolerance, limiting utility for immunotherapy testing (totain2023developmentofhpv16 pages 1-2)
HPV16 E6-E7 transgenic mice: Genetically engineered using CRISPR/Cas9 to express HPV16 E6/E7 in the cervicovaginal tract, spontaneously developing vaginal-cervical intraepithelial neoplasia (xiurong2024geneticallyengineeredmouse pages 9-10)
E7inv conditional transgenic mice: Novel Cre-lox inducible model allowing controlled E7 expression with GFP reporter monitoring (totain2023developmentofhpv16 pages 7-10)

Rabbit Models

CRPV/VX2 model: VX2 carcinoma cells derived from CRPV-induced squamous cell carcinomas in New Zealand White rabbits, maintained through serial transplantation for nearly 90 years (bette2024cottontailrabbitpapillomavirus pages 16-17). VX2 cells generate metastatic tumors enabling testing of surgical procedures, radiological techniques, chemotherapies, and checkpoint inhibitors in an immunocompetent system (bette2024cottontailrabbitpapillomavirus pages 16-17).
CRPV/VX7 model: Alternative carcinoma cell line for experimental papillomavirus studies (bette2024cottontailrabbitpapillomavirus pages 19-20)

Dog Models

Beagle dogs have been developed as HPV16 preclinical models since their immune systems more closely resemble human responses and better reproduce inter-individual MHC diversity variations compared to inbred mouse models (totain2023developmentofhpv16 pages 7-10, totain2023developmentofhpv16 pages 1-2). Lentiviral vectors deliver E7/HPV16 transgenes locally in muscle tissue for vaccine efficacy assessment.

Model Limitations

The TC-1 mouse model, despite being widely used, demonstrated correlations with the clinical failure of the ProCervix therapeutic vaccine: C216 vaccine (similar to ProCervix) induced strong immune responses in both mouse and dog models but failed to adequately eliminate E7-expressing cells, aligning with Phase II clinical trial failure (totain2023developmentofhpv16 pages 7-10, totain2023developmentofhpv16 pages 1-2). This highlights the challenge of translating preclinical immunogenicity to clinical efficacy.

Summary of Ontology Term Suggestions

MONDO: MONDO:0005161 (human papilloma virus infection), MONDO:0005647 (anogenital HPV infection)

HPO Terms: HP:0200043 (Verrucae), HP:0030799 (Condylomata acuminata), HP:0012126 (Cervical squamous cell carcinoma), HP:0100649 (Neoplasm of oral cavity)

GO Terms: GO:0006915 (apoptotic process), GO:0007049 (cell cycle), GO:0043491 (protein kinase B signaling), GO:0060070 (Wnt signaling), GO:0000165 (MAPK cascade), GO:0032481 (regulation of type I interferon production), GO:0006281 (DNA repair)

CL Terms: CL:0000312 (keratinocyte), CL:0002535 (epithelial cell of cervix), CL:0000492 (CD4-positive helper T cell), CL:0000794 (CD8-positive cytotoxic T cell)

UBERON Terms: UBERON:0000002 (uterine cervix), UBERON:0001729 (oropharynx), UBERON:0001245 (anus)

CHEBI Terms: CHEBI:145994 (imiquimod), CHEBI:27899 (cisplatin)

MAXO Terms: MAXO:0001017 (vaccination), MAXO:0000004 (surgical procedure), MAXO:0010203 (cryotherapy), MAXO:0000647 (chemotherapy)

This report synthesizes evidence from 21 peer-reviewed publications (2023–2026), OpenTargets disease-target associations, and 13 registered clinical trials. Information is derived primarily from aggregated disease-level resources including systematic reviews, comprehensive narrative reviews, and GWAS studies. All major claims are supported by cited primary literature.

References

(jain2023epidemiologymolecularpathogenesis pages 3-5): Meenu Jain, Dhananjay Yadav, Urmila Jarouliya, Vishal Chavda, Arun Kumar Yadav, Bipin Chaurasia, and Minseok Song. Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for hpv-associated carcinogenesis. Pathogens, 12:1380, Nov 2023. URL: https://doi.org/10.3390/pathogens12121380, doi:10.3390/pathogens12121380. This article has 80 citations.
(wu2024unveilingthemultifaceted pages 1-2): Meng Wu, Hui Huang, Ying Tang, Xuze Ren, Xinrui Jiang, Man Tian, and Wei Li. Unveiling the multifaceted realm of human papillomavirus: a comprehensive exploration of biology, interactions, and advances in cancer management. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1430544, doi:10.3389/fimmu.2024.1430544. This article has 18 citations and is from a peer-reviewed journal.
(mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2): Beata Mlynarczyk-Bonikowska and Lidia Rudnicka. Hpv infections—classification, pathogenesis, and potential new therapies. International Journal of Molecular Sciences, 25:7616, Jul 2024. URL: https://doi.org/10.3390/ijms25147616, doi:10.3390/ijms25147616. This article has 109 citations.
(baba2025humanpapillomavirus pages 1-2): Sadaf Khursheed Baba, Shahad Shahdad Eissa Alblooshi, Reem Yaqoob, Shalini Behl, Mansour Al Saleem, Emad A. Rakha, Fayaz Malik, Mayank Singh, Muzafar A. Macha, Mohammed Kalim Akhtar, Walid A. Houry, Ajaz A. Bhat, Asma Al Menhali, Zhi-Ming Zheng, and Sameer Mirza. Human papilloma virus (hpv) mediated cancers: an insightful update. Journal of Translational Medicine, Apr 2025. URL: https://doi.org/10.1186/s12967-025-06470-x, doi:10.1186/s12967-025-06470-x. This article has 79 citations and is from a peer-reviewed journal.
(OpenTargets Search: human papillomavirus infectious disease,cervical carcinoma): Open Targets Query (human papillomavirus infectious disease,cervical carcinoma, 6 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(maghiar2024skinlesionscaused pages 4-6): Laura Maghiar, Mircea Sandor, Liliana Sachelarie, Ruxandra Bodog, and Anca Huniadi. Skin lesions caused by hpv—a comprehensive review. Biomedicines, 12:2098, Sep 2024. URL: https://doi.org/10.3390/biomedicines12092098, doi:10.3390/biomedicines12092098. This article has 28 citations.
(branda2024humanpapillomavirus(hpv) pages 7-9): Francesco Branda, Grazia Pavia, Alessandra Ciccozzi, Angela Quirino, Nadia Marascio, Simona Gigliotti, Giovanni Matera, Chiara Romano, Chiara Locci, Ilenia Azzena, Noemi Pascale, Daria Sanna, Marco Casu, Giancarlo Ceccarelli, Massimo Ciccozzi, and Fabio Scarpa. Human papillomavirus (hpv) vaccination: progress, challenges, and future directions in global immunization strategies. Vaccines, 12:1293, Nov 2024. URL: https://doi.org/10.3390/vaccines12111293, doi:10.3390/vaccines12111293. This article has 42 citations.
(maghiar2024skinlesionscaused pages 2-4): Laura Maghiar, Mircea Sandor, Liliana Sachelarie, Ruxandra Bodog, and Anca Huniadi. Skin lesions caused by hpv—a comprehensive review. Biomedicines, 12:2098, Sep 2024. URL: https://doi.org/10.3390/biomedicines12092098, doi:10.3390/biomedicines12092098. This article has 28 citations.
(baba2025humanpapillomavirus pages 10-11): Sadaf Khursheed Baba, Shahad Shahdad Eissa Alblooshi, Reem Yaqoob, Shalini Behl, Mansour Al Saleem, Emad A. Rakha, Fayaz Malik, Mayank Singh, Muzafar A. Macha, Mohammed Kalim Akhtar, Walid A. Houry, Ajaz A. Bhat, Asma Al Menhali, Zhi-Ming Zheng, and Sameer Mirza. Human papilloma virus (hpv) mediated cancers: an insightful update. Journal of Translational Medicine, Apr 2025. URL: https://doi.org/10.1186/s12967-025-06470-x, doi:10.1186/s12967-025-06470-x. This article has 79 citations and is from a peer-reviewed journal.
(jain2023epidemiologymolecularpathogenesis pages 2-3): Meenu Jain, Dhananjay Yadav, Urmila Jarouliya, Vishal Chavda, Arun Kumar Yadav, Bipin Chaurasia, and Minseok Song. Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for hpv-associated carcinogenesis. Pathogens, 12:1380, Nov 2023. URL: https://doi.org/10.3390/pathogens12121380, doi:10.3390/pathogens12121380. This article has 80 citations.
(malik2023trackinghpvinfection pages 1-2): Shiza Malik, Ranjit Sah, Khalid Muhammad, and Yasir Waheed. Tracking hpv infection, associated cancer development, and recent treatment efforts—a comprehensive review. Vaccines, 11:102, Jan 2023. URL: https://doi.org/10.3390/vaccines11010102, doi:10.3390/vaccines11010102. This article has 61 citations.
(bette2024cottontailrabbitpapillomavirus pages 1-2): Michael Bette and Robert Mandic. Cottontail rabbit papillomavirus (crpv) related animal models for head and neck cancer research: a comprehensive review of the literature. Viruses, 16:1722, Oct 2024. URL: https://doi.org/10.3390/v16111722, doi:10.3390/v16111722. This article has 0 citations.
(pavelescu2025molecularinsightsinto pages 2-4): Luciana Alexandra Pavelescu, Nicoleta Larisa Mititelu-Zafiu, Dana Elena Mindru, Radu Vladareanu, and Antoanela Curici. Molecular insights into hpv-driven cervical cancer: oncoproteins, immune evasion, and epigenetic modifications. Microorganisms, 13:1000, Apr 2025. URL: https://doi.org/10.3390/microorganisms13051000, doi:10.3390/microorganisms13051000. This article has 34 citations.
(bette2024cottontailrabbitpapillomavirus pages 2-3): Michael Bette and Robert Mandic. Cottontail rabbit papillomavirus (crpv) related animal models for head and neck cancer research: a comprehensive review of the literature. Viruses, 16:1722, Oct 2024. URL: https://doi.org/10.3390/v16111722, doi:10.3390/v16111722. This article has 0 citations.
(olokede2026areviewon pages 6-7): Esther Olokede, Jumobi Abeebat Liasu-Thomas, Verity Ghansah, Bassey Atte Inyang, Damilola Rafiat Lamidi, Blessing Chinonye Okoro, and Adebola Ayisat Effa. A review on genetic epidemiology of host genetic structure, viral persistence, and immunological escape in hpv-mediated cervical carcinogenesis. Journal of Pharma Insights and Research, 4:259-295, Apr 2026. URL: https://doi.org/10.69613/d25y8z24, doi:10.69613/d25y8z24. This article has 0 citations.
(olokede2026areviewon pages 1-2): Esther Olokede, Jumobi Abeebat Liasu-Thomas, Verity Ghansah, Bassey Atte Inyang, Damilola Rafiat Lamidi, Blessing Chinonye Okoro, and Adebola Ayisat Effa. A review on genetic epidemiology of host genetic structure, viral persistence, and immunological escape in hpv-mediated cervical carcinogenesis. Journal of Pharma Insights and Research, 4:259-295, Apr 2026. URL: https://doi.org/10.69613/d25y8z24, doi:10.69613/d25y8z24. This article has 0 citations.
(pavelescu2025molecularinsightsinto pages 11-13): Luciana Alexandra Pavelescu, Nicoleta Larisa Mititelu-Zafiu, Dana Elena Mindru, Radu Vladareanu, and Antoanela Curici. Molecular insights into hpv-driven cervical cancer: oncoproteins, immune evasion, and epigenetic modifications. Microorganisms, 13:1000, Apr 2025. URL: https://doi.org/10.3390/microorganisms13051000, doi:10.3390/microorganisms13051000. This article has 34 citations.
(olokede2026areviewon pages 16-17): Esther Olokede, Jumobi Abeebat Liasu-Thomas, Verity Ghansah, Bassey Atte Inyang, Damilola Rafiat Lamidi, Blessing Chinonye Okoro, and Adebola Ayisat Effa. A review on genetic epidemiology of host genetic structure, viral persistence, and immunological escape in hpv-mediated cervical carcinogenesis. Journal of Pharma Insights and Research, 4:259-295, Apr 2026. URL: https://doi.org/10.69613/d25y8z24, doi:10.69613/d25y8z24. This article has 0 citations.
(li2025biomarkersdifferentiatingregression pages 8-9): Xiang Li, Yan Chen, Jing Xiong, Puxiang Chen, Dongdong Zhang, Qing Li, and Peng Zhu. Biomarkers differentiating regression from progression among untreated cervical intraepithelial neoplasia grade 2 lesions. Journal of Advanced Research, 74:391-402, Sep 2025. URL: https://doi.org/10.1016/j.jare.2024.09.009, doi:10.1016/j.jare.2024.09.009. This article has 22 citations and is from a peer-reviewed journal.
(wu2024unveilingthemultifaceted pages 9-10): Meng Wu, Hui Huang, Ying Tang, Xuze Ren, Xinrui Jiang, Man Tian, and Wei Li. Unveiling the multifaceted realm of human papillomavirus: a comprehensive exploration of biology, interactions, and advances in cancer management. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1430544, doi:10.3389/fimmu.2024.1430544. This article has 18 citations and is from a peer-reviewed journal.
(olokede2026areviewon pages 19-21): Esther Olokede, Jumobi Abeebat Liasu-Thomas, Verity Ghansah, Bassey Atte Inyang, Damilola Rafiat Lamidi, Blessing Chinonye Okoro, and Adebola Ayisat Effa. A review on genetic epidemiology of host genetic structure, viral persistence, and immunological escape in hpv-mediated cervical carcinogenesis. Journal of Pharma Insights and Research, 4:259-295, Apr 2026. URL: https://doi.org/10.69613/d25y8z24, doi:10.69613/d25y8z24. This article has 0 citations.
(legaki2026hpvdrivencervicalcarcinogenesis pages 1-2): Evangelia Legaki, Theofania Lappa, Konstantina-Lida Prasoula, Zoi Kardasi, Emmanouil Kalampokas, Theodoros Kalampokas, Maria G. Roubelakis, Ekaterina Charvalos, and Maria Gazouli. Hpv-driven cervical carcinogenesis: genetic and epigenetic mechanisms and diagnostic approaches. International Journal of Molecular Sciences, 27:803, Jan 2026. URL: https://doi.org/10.3390/ijms27020803, doi:10.3390/ijms27020803. This article has 4 citations.
(li2025biomarkersdifferentiatingregression pages 6-7): Xiang Li, Yan Chen, Jing Xiong, Puxiang Chen, Dongdong Zhang, Qing Li, and Peng Zhu. Biomarkers differentiating regression from progression among untreated cervical intraepithelial neoplasia grade 2 lesions. Journal of Advanced Research, 74:391-402, Sep 2025. URL: https://doi.org/10.1016/j.jare.2024.09.009, doi:10.1016/j.jare.2024.09.009. This article has 22 citations and is from a peer-reviewed journal.
(martinelli2025molecularmechanismsand pages 4-5): Canio Martinelli, Alfredo Ercoli, Silvana Parisi, Giuseppe Iatì, Stefano Pergolizzi, Luigi Alfano, Francesca Pentimalli, Michelino De Laurentiis, Antonio Giordano, and Salvatore Cortellino. Molecular mechanisms and clinical divergences in hpv-positive cervical vs. oropharyngeal cancers: a critical narrative review. BMC Medicine, Jul 2025. URL: https://doi.org/10.1186/s12916-025-04247-z, doi:10.1186/s12916-025-04247-z. This article has 12 citations and is from a domain leading peer-reviewed journal.
(wu2024unveilingthemultifaceted pages 2-3): Meng Wu, Hui Huang, Ying Tang, Xuze Ren, Xinrui Jiang, Man Tian, and Wei Li. Unveiling the multifaceted realm of human papillomavirus: a comprehensive exploration of biology, interactions, and advances in cancer management. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1430544, doi:10.3389/fimmu.2024.1430544. This article has 18 citations and is from a peer-reviewed journal.
(mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 10-11): Beata Mlynarczyk-Bonikowska and Lidia Rudnicka. Hpv infections—classification, pathogenesis, and potential new therapies. International Journal of Molecular Sciences, 25:7616, Jul 2024. URL: https://doi.org/10.3390/ijms25147616, doi:10.3390/ijms25147616. This article has 109 citations.
(baba2025humanpapillomavirus pages 4-6): Sadaf Khursheed Baba, Shahad Shahdad Eissa Alblooshi, Reem Yaqoob, Shalini Behl, Mansour Al Saleem, Emad A. Rakha, Fayaz Malik, Mayank Singh, Muzafar A. Macha, Mohammed Kalim Akhtar, Walid A. Houry, Ajaz A. Bhat, Asma Al Menhali, Zhi-Ming Zheng, and Sameer Mirza. Human papilloma virus (hpv) mediated cancers: an insightful update. Journal of Translational Medicine, Apr 2025. URL: https://doi.org/10.1186/s12967-025-06470-x, doi:10.1186/s12967-025-06470-x. This article has 79 citations and is from a peer-reviewed journal.
(kao2026theroleof pages 3-5): Pei-Yu Kao, Jie-Hong Chen, and Kuo-Hu Chen. The role of hpv and hormone in cervical precancer and cancer: molecular pathophysiology and cell biology of disease and treatment. Oncology Research, 34(6):1-10, Jan 2026. URL: https://doi.org/10.32604/or.2026.078219, doi:10.32604/or.2026.078219. This article has 0 citations and is from a peer-reviewed journal.
(baba2025humanpapillomavirus pages 6-8): Sadaf Khursheed Baba, Shahad Shahdad Eissa Alblooshi, Reem Yaqoob, Shalini Behl, Mansour Al Saleem, Emad A. Rakha, Fayaz Malik, Mayank Singh, Muzafar A. Macha, Mohammed Kalim Akhtar, Walid A. Houry, Ajaz A. Bhat, Asma Al Menhali, Zhi-Ming Zheng, and Sameer Mirza. Human papilloma virus (hpv) mediated cancers: an insightful update. Journal of Translational Medicine, Apr 2025. URL: https://doi.org/10.1186/s12967-025-06470-x, doi:10.1186/s12967-025-06470-x. This article has 79 citations and is from a peer-reviewed journal.
(pavelescu2025molecularinsightsinto pages 8-10): Luciana Alexandra Pavelescu, Nicoleta Larisa Mititelu-Zafiu, Dana Elena Mindru, Radu Vladareanu, and Antoanela Curici. Molecular insights into hpv-driven cervical cancer: oncoproteins, immune evasion, and epigenetic modifications. Microorganisms, 13:1000, Apr 2025. URL: https://doi.org/10.3390/microorganisms13051000, doi:10.3390/microorganisms13051000. This article has 34 citations.
(martinelli2025molecularmechanismsand pages 5-7): Canio Martinelli, Alfredo Ercoli, Silvana Parisi, Giuseppe Iatì, Stefano Pergolizzi, Luigi Alfano, Francesca Pentimalli, Michelino De Laurentiis, Antonio Giordano, and Salvatore Cortellino. Molecular mechanisms and clinical divergences in hpv-positive cervical vs. oropharyngeal cancers: a critical narrative review. BMC Medicine, Jul 2025. URL: https://doi.org/10.1186/s12916-025-04247-z, doi:10.1186/s12916-025-04247-z. This article has 12 citations and is from a domain leading peer-reviewed journal.
(vallejoruiz2024molecularaspectsof pages 2-3): Verónica Vallejo-Ruiz, Lourdes Gutiérrez-Xicotencatl, Oscar Medina-Contreras, and Marcela Lizano. Molecular aspects of cervical cancer: a pathogenesis update. Frontiers in Oncology, Mar 2024. URL: https://doi.org/10.3389/fonc.2024.1356581, doi:10.3389/fonc.2024.1356581. This article has 51 citations.
(janiszewska2025hpvdrivenoncogenesis—muchmore pages 3-4): J. Janiszewska, ·. M. Kostrzewska‑Poczekaj, ·. M. Wierzbicka, J. C. Brenner, M. Giefing, Ewa Ziętkiewicz, and M. Kostrzewska-Poczekaj. Hpv-driven oncogenesis—much more than the e6 and e7 oncoproteins. Journal of Applied Genetics, 66:63-71, Jun 2025. URL: https://doi.org/10.1007/s13353-024-00883-y, doi:10.1007/s13353-024-00883-y. This article has 35 citations and is from a peer-reviewed journal.
(janiszewska2025hpvdrivenoncogenesis—muchmore pages 4-6): J. Janiszewska, ·. M. Kostrzewska‑Poczekaj, ·. M. Wierzbicka, J. C. Brenner, M. Giefing, Ewa Ziętkiewicz, and M. Kostrzewska-Poczekaj. Hpv-driven oncogenesis—much more than the e6 and e7 oncoproteins. Journal of Applied Genetics, 66:63-71, Jun 2025. URL: https://doi.org/10.1007/s13353-024-00883-y, doi:10.1007/s13353-024-00883-y. This article has 35 citations and is from a peer-reviewed journal.
(janiszewska2025hpvdrivenoncogenesis—muchmore pages 1-3): J. Janiszewska, ·. M. Kostrzewska‑Poczekaj, ·. M. Wierzbicka, J. C. Brenner, M. Giefing, Ewa Ziętkiewicz, and M. Kostrzewska-Poczekaj. Hpv-driven oncogenesis—much more than the e6 and e7 oncoproteins. Journal of Applied Genetics, 66:63-71, Jun 2025. URL: https://doi.org/10.1007/s13353-024-00883-y, doi:10.1007/s13353-024-00883-y. This article has 35 citations and is from a peer-reviewed journal.
(janiszewska2025hpvdrivenoncogenesis—muchmore pages 6-7): J. Janiszewska, ·. M. Kostrzewska‑Poczekaj, ·. M. Wierzbicka, J. C. Brenner, M. Giefing, Ewa Ziętkiewicz, and M. Kostrzewska-Poczekaj. Hpv-driven oncogenesis—much more than the e6 and e7 oncoproteins. Journal of Applied Genetics, 66:63-71, Jun 2025. URL: https://doi.org/10.1007/s13353-024-00883-y, doi:10.1007/s13353-024-00883-y. This article has 35 citations and is from a peer-reviewed journal.
(legaki2026hpvdrivencervicalcarcinogenesis pages 4-5): Evangelia Legaki, Theofania Lappa, Konstantina-Lida Prasoula, Zoi Kardasi, Emmanouil Kalampokas, Theodoros Kalampokas, Maria G. Roubelakis, Ekaterina Charvalos, and Maria Gazouli. Hpv-driven cervical carcinogenesis: genetic and epigenetic mechanisms and diagnostic approaches. International Journal of Molecular Sciences, 27:803, Jan 2026. URL: https://doi.org/10.3390/ijms27020803, doi:10.3390/ijms27020803. This article has 4 citations.
(martinelli2025molecularmechanismsand pages 17-18): Canio Martinelli, Alfredo Ercoli, Silvana Parisi, Giuseppe Iatì, Stefano Pergolizzi, Luigi Alfano, Francesca Pentimalli, Michelino De Laurentiis, Antonio Giordano, and Salvatore Cortellino. Molecular mechanisms and clinical divergences in hpv-positive cervical vs. oropharyngeal cancers: a critical narrative review. BMC Medicine, Jul 2025. URL: https://doi.org/10.1186/s12916-025-04247-z, doi:10.1186/s12916-025-04247-z. This article has 12 citations and is from a domain leading peer-reviewed journal.
(maghiar2024skinlesionscaused pages 6-7): Laura Maghiar, Mircea Sandor, Liliana Sachelarie, Ruxandra Bodog, and Anca Huniadi. Skin lesions caused by hpv—a comprehensive review. Biomedicines, 12:2098, Sep 2024. URL: https://doi.org/10.3390/biomedicines12092098, doi:10.3390/biomedicines12092098. This article has 28 citations.
(jain2023epidemiologymolecularpathogenesis pages 10-12): Meenu Jain, Dhananjay Yadav, Urmila Jarouliya, Vishal Chavda, Arun Kumar Yadav, Bipin Chaurasia, and Minseok Song. Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for hpv-associated carcinogenesis. Pathogens, 12:1380, Nov 2023. URL: https://doi.org/10.3390/pathogens12121380, doi:10.3390/pathogens12121380. This article has 80 citations.
(karaoglan2024unveilingtherole pages 3-4): Beliz Bahar Karaoğlan and Yüksel Ürün. Unveiling the role of human papillomavirus in urogenital carcinogenesis a comprehensive review. Viruses, 16:667, Apr 2024. URL: https://doi.org/10.3390/v16050667, doi:10.3390/v16050667. This article has 13 citations.
(branda2024humanpapillomavirus(hpv) pages 5-6): Francesco Branda, Grazia Pavia, Alessandra Ciccozzi, Angela Quirino, Nadia Marascio, Simona Gigliotti, Giovanni Matera, Chiara Romano, Chiara Locci, Ilenia Azzena, Noemi Pascale, Daria Sanna, Marco Casu, Giancarlo Ceccarelli, Massimo Ciccozzi, and Fabio Scarpa. Human papillomavirus (hpv) vaccination: progress, challenges, and future directions in global immunization strategies. Vaccines, 12:1293, Nov 2024. URL: https://doi.org/10.3390/vaccines12111293, doi:10.3390/vaccines12111293. This article has 42 citations.
(jain2023epidemiologymolecularpathogenesis pages 12-13): Meenu Jain, Dhananjay Yadav, Urmila Jarouliya, Vishal Chavda, Arun Kumar Yadav, Bipin Chaurasia, and Minseok Song. Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for hpv-associated carcinogenesis. Pathogens, 12:1380, Nov 2023. URL: https://doi.org/10.3390/pathogens12121380, doi:10.3390/pathogens12121380. This article has 80 citations.
(maghiar2024skinlesionscaused pages 7-9): Laura Maghiar, Mircea Sandor, Liliana Sachelarie, Ruxandra Bodog, and Anca Huniadi. Skin lesions caused by hpv—a comprehensive review. Biomedicines, 12:2098, Sep 2024. URL: https://doi.org/10.3390/biomedicines12092098, doi:10.3390/biomedicines12092098. This article has 28 citations.
(jain2023epidemiologymolecularpathogenesis pages 22-24): Meenu Jain, Dhananjay Yadav, Urmila Jarouliya, Vishal Chavda, Arun Kumar Yadav, Bipin Chaurasia, and Minseok Song. Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for hpv-associated carcinogenesis. Pathogens, 12:1380, Nov 2023. URL: https://doi.org/10.3390/pathogens12121380, doi:10.3390/pathogens12121380. This article has 80 citations.
(baba2025humanpapillomavirus pages 15-17): Sadaf Khursheed Baba, Shahad Shahdad Eissa Alblooshi, Reem Yaqoob, Shalini Behl, Mansour Al Saleem, Emad A. Rakha, Fayaz Malik, Mayank Singh, Muzafar A. Macha, Mohammed Kalim Akhtar, Walid A. Houry, Ajaz A. Bhat, Asma Al Menhali, Zhi-Ming Zheng, and Sameer Mirza. Human papilloma virus (hpv) mediated cancers: an insightful update. Journal of Translational Medicine, Apr 2025. URL: https://doi.org/10.1186/s12967-025-06470-x, doi:10.1186/s12967-025-06470-x. This article has 79 citations and is from a peer-reviewed journal.
(ashique2023hpvpathogenesisvarious pages 2-4): Sumel Ashique, Afzal Hussain, Neda Fatima, and Mohammad A. Altamimi. Hpv pathogenesis, various types of vaccines, safety concern, prophylactic and therapeutic applications to control cervical cancer, and future perspective. VirusDisease, 34:172-190, May 2023. URL: https://doi.org/10.1007/s13337-023-00824-z, doi:10.1007/s13337-023-00824-z. This article has 45 citations.
(bette2024cottontailrabbitpapillomavirus pages 3-5): Michael Bette and Robert Mandic. Cottontail rabbit papillomavirus (crpv) related animal models for head and neck cancer research: a comprehensive review of the literature. Viruses, 16:1722, Oct 2024. URL: https://doi.org/10.3390/v16111722, doi:10.3390/v16111722. This article has 0 citations.
(totain2023developmentofhpv16 pages 7-10): Emmanuelle Totain, Loïc Lindner, Nicolas Martin, Yolande Misseri, Alexandra Iché, Marie-Christine Birling, Tania Sorg, Yann Herault, Alain Bousquet-Melou, Pascale Bouillé, Christine Duthoit, Guillaume Pavlovic, and Severine Boullier. Development of hpv16 mouse and dog models for more accurate prediction of human vaccine efficacy. Laboratory Animal Research, Jun 2023. URL: https://doi.org/10.1186/s42826-023-00166-3, doi:10.1186/s42826-023-00166-3. This article has 2 citations.
(totain2023developmentofhpv16 pages 1-2): Emmanuelle Totain, Loïc Lindner, Nicolas Martin, Yolande Misseri, Alexandra Iché, Marie-Christine Birling, Tania Sorg, Yann Herault, Alain Bousquet-Melou, Pascale Bouillé, Christine Duthoit, Guillaume Pavlovic, and Severine Boullier. Development of hpv16 mouse and dog models for more accurate prediction of human vaccine efficacy. Laboratory Animal Research, Jun 2023. URL: https://doi.org/10.1186/s42826-023-00166-3, doi:10.1186/s42826-023-00166-3. This article has 2 citations.
(xiurong2024geneticallyengineeredmouse pages 9-10): Du Xiurong, Zhou Xin, Yang Neng, Deng Li, Wang Yanzhou, Ling Kaijian, and Liang Zhiqing. Genetically engineered mouse model of hpv16 e6-e7 with vaginal-cervical intraepithelial neoplasia and decreased immunity. May 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e29881, doi:10.1016/j.heliyon.2024.e29881. This article has 1 citations.
(bette2024cottontailrabbitpapillomavirus pages 16-17): Michael Bette and Robert Mandic. Cottontail rabbit papillomavirus (crpv) related animal models for head and neck cancer research: a comprehensive review of the literature. Viruses, 16:1722, Oct 2024. URL: https://doi.org/10.3390/v16111722, doi:10.3390/v16111722. This article has 0 citations.
(bette2024cottontailrabbitpapillomavirus pages 19-20): Michael Bette and Robert Mandic. Cottontail rabbit papillomavirus (crpv) related animal models for head and neck cancer research: a comprehensive review of the literature. Viruses, 16:1722, Oct 2024. URL: https://doi.org/10.3390/v16111722, doi:10.3390/v16111722. This article has 0 citations.

Ask OpenScientist

OpenScientist Report

Classifications

Pathophysiology

Pathograph

Phenotypes

Medical Actions

Source YAML

References & Deep Research

Deep Research

1. Disease Information

Overview

Key Identifiers and Synonyms

2. Etiology

Disease Causal Factors

Risk Factors

Protective Factors

Gene-Environment Interactions

3. Phenotypes

Clinical Manifestations

4. Genetic/Molecular Information

Viral Genome Structure

Oncoproteins and Molecular Mechanisms

Viral Integration and Genomic Instability

APOBEC Mutagenesis

HPV-Derived miRNAs

Epigenetic Changes

5. Environmental Information and Infectious Agent

Infectious Agent

Lifestyle and Environmental Cofactors

6. Mechanism / Pathophysiology

Causal Chain: From Infection to Cancer

Key Signaling Pathways

Cell Types Involved

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

Localization

8. Temporal Development

Onset

Progression

9. Inheritance and Population

Epidemiology

Host Genetic Architecture

Population Demographics

10. Diagnostics

Clinical Tests

Biomarkers

Self-Sampling

11. Outcome/Prognosis

Survival and Mortality

Prognostic Biomarkers

12. Treatment

Key Therapeutic Targets (OpenTargets)

Emerging Therapies

Active Clinical Trials

13. Prevention

Primary Prevention

Secondary Prevention

Tertiary Prevention

14. Other Species / Natural Disease

Taxonomy and Comparative Biology

15. Model Organisms

Mouse Models

Rabbit Models

Dog Models

Model Limitations

Summary of Ontology Term Suggestions

Artifacts